Members' News
14th Nov 2024
Gordon Pirie joins AM Sci Tech as Asset Manager at Aberdeen Energy and Innovation Parks
AM Sci Tech, a subsidiary of Hurstwood Holdings is pleased to announce the appointment of Gordon Pirie as Asset Manager at Aberdeen Energy & Innovation Parks.
5th Nov 2024
BioAscent awarded prestigious Knowledge Transfer Partnership
BioAscent awarded prestigious Knowledge Transfer Partnership with Centre for Targeted Protein Degradation at the University of Dundee.
21st Oct 2024
Merck announces investment of over £4 million in its facility in Livingston
The investment in diagnostics and blood typing will allow the company to increase its production capacity of diagnostic monoclonal antibodies (mAbs) by approximately 35 per cent. mAbs are used by health and science professionals around the world to determine blood typing.
14th Sep 2024
NuCana Presents Encouraging Data at ESMO Congress 2024
NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
26th Jul 2024
Medannex awarded grant to accelerate new treatment for bone cancer in children
Medannex today announced an Innovate UK grant to fund a £313,000 project developing a new treatment for paediatric osteosarcoma. The ‘Transforming Cancer Therapeutics’ award will allow the Scottish biotech company to prepare its first-in-class therapy (MDX-124) for a clinical study in this rare childhood cancer.
1st Jun 2024
Medannex unveils First-in-Human study of novel cancer therapy at ASCO 2024
Medannex Ltd (Edinburgh) today revealed details of the ATTAINMENT study at the American Society of Clinical Oncology (ASCO) Annual Meeting.
29th Apr 2024
Nebu-Flow secures £4.7m to accelerate next generation respiratory pharmaceuticals
Nebu-Flow has secured an additional £4.7 million of investment to accelerate the next generation of inhaled drugs for patients with respiratory disorders, which are the main cause of death and disability worldwide.
8th Apr 2024
BioAscent reports promising growth as it marks tenth anniversary
(Newhouse, UK, 8 April 2024) Integrated drug discovery services provider BioAscent, which marked its tenth anniversary in 2023, has reported promising growth in the wake of sustained demand for its services.
4th Apr 2024
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors.
30th Mar 2024
CALCIVIS has secured £5m in funding to roll out its cutting edge dental technology
Edinburgh-based biotechnology firm, CALCIVIS®, has secured £5m in funding to roll out its cutting-edge dental technology.
18th Mar 2024
Medannex Strengthens Global Intellectual Property Portfolio for Novel Clinical Asset
First-in-class therapy now patent-protected in all major markets, including USA, Europe, China, Japan and Canada
21st Feb 2024
BioAscent invests in new state-of-the-art protein production facility
(Newhouse, UK, 21 February 2024) Integrated drug discovery services provider BioAscent has opened its state-of-the-art protein production facility in an event officiated by Professor Michael Barrett OBE.
19th Jan 2024
Medannex Nature publication demonstrates anti-cancer effects of MDX-124 in multiple tumour types
Nature publication demonstrates anti-cancer effects of MDX-124 in multiple tumour types
31st Dec 2023
Tower Mains training dates for GxP training and inspection
Tower Mains provides in-house and online training on an individual or group basis, covering a wide range of topics related to the regulatory industry and self-development. In addition to our ‘standard’ training we can also provide client-specific training and open courses in GCP Inspection Preparation, People Development Training using DISC and Clinical Trial Monitor Training.
11th Dec 2023
Pioneer Group and Innovate UK Join Forces to Accelerate the Development of Life Sciences Companies
Pioneer Group, a company combining laboratory development and operation with venture building, is continuing its collaboration with Innovate UK, by bringing its venture development ‘Launch Programme’ to the Exploit stage of Innovate UK’s ICURe programme.
13th Nov 2023
Kelso Pharma initiates European expansion
Kelso Pharma initiates European expansion with acquisition of Italian specialty pharma company, Velit Biopharma
10th Nov 2023
Valneva Announces US FDA Approval of Chikungunya Vaccine IXCHIQ
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ
20th Sep 2023
FDA Grants US Orphan Designation to Medannex First-in-Class Therapy
FDA Grants US Orphan Designation to Medannex’s First-in-Class Therapy
14th Sep 2023
Association to Horizon Europe - Information Webinar
Recording and slides now available please click here.
21st Aug 2023
Medannex Announces First Patient Treated in Phase 1b Clinical Study of Groundbreaking Anti-Annexin-A
Medannex Announces First Patient Treated in Phase 1b Clinical Study of Groundbreaking Anti-Annexin-A1 Therapy
8th Aug 2023
Archangels: Cytomos secures 4Million Pounds to advance new approach to cell analysis
Archangels, Cytomos, an Edinburgh-based life science company that has developed a proprietary new approach to analysing cells, has secured £4 million to scale up market-testing of its technology platform Cytomos Dielectric Spectroscopy (CDS).
31st Jul 2023
Archangels secures 12million co-investment agreement with British Business Investments
Archangels, a leading business angel syndicate investing in early-stage Scottish life sciences and technology companies, is bolstering its funding fire power after securing a £12m co-investment agreement with British Business Investments via its Regional Angels Programme.
16th Jul 2023
TauRx presents significant reduction in neurodegeneration in Alzheimers Disease
TauRx’s hydromethylthionine mesylate (HMTM) demonstrates significant reduction in neurodegeneration in Alzheimer’s Disease (AD)
3rd Jul 2023
Pioneer Group and King's College London incubator partnership
Pioneer Group's latest partnership with King's College London to develop 95,000 square feet of incubator facilities on London's South Bank and support breakthrough spin-outs developing novel solutions to human health challenges.
31st May 2023
Merck Increases Global Commitment to Biosafety Testing With 35 Million Euro Investment in Scotland
Press release here:
19th Apr 2023
30 Technology Antimicrobial Nitric Oxide Platform Acquired by Convatec Group
30 Technology’s Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications
31st Mar 2023
UK Government joined the CPTPP
The UK Government has joined the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP).
30th Mar 2023
RoslinCT and Lykan Bioscience announce that the MHRA has granted an MIA License
RoslinCT and Lykan Bioscience announce that the MHRA has granted an MIA License for their cGMP Manufacturing facilities in Edinburgh, UK
10th Mar 2023
Calcivis targets US expansion after securing FDA PMA approval
Calcivis targets US expansion after securing FDA PMA approval
2nd Mar 2023
Merck Livingston announces 15 new jobs and 2.6 million stg investment
Merck Livingston announces 15 new jobs and £2.6 million investment
1st Mar 2023
Medannex receives Orphan Designation from the European Medicines Agency for Pancreatic Cancer
1st Feb 2023
Firefinch Software announces partnership with i4 Product Design
Firefinch Software and i4 Product Design (i4PD) have announced that they have entered into a strategic partnership that will bring together the market leading software expertise of Firefinch Software with the hardware product design and development experience of i4PD, creating a one stop shop for start-ups and new businesses looking to bring their ideas quickly to market.
18th Jan 2023
Blackford announces acquisition by Bayer
Blackford announces acquisition by Bayer, the global life science company.
14th Nov 2022
TauRx Announces Additional Investment of USD119 million
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
6th Oct 2022
TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulato
TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions
1st Oct 2022
Cytomos GBP1.6 million additional funding secured
This £1.6m funding – led by Archangels, alongside Scottish Enterprise and Old College Capital – will enable the development and qualification of Cytomos Dielectric Spectroscopy (CDSTM) to move forward at pace and address the biopharma industry’s unmet needs.
13th Sep 2022
Lykan Bioscience and RoslinCT Announce the Establishment of a Scientific Advisory Board
HOPKINTON, MA and EDINBURGH, UK September 13, 2022 - Lykan Bioscience and RoslinCT, a leader in Contract Development and Manufacturing for cell therapies, announced the formation of its inaugural Scientific Advisory Board (SAB). The newly created SAB is comprised of cell and gene therapy pioneers with extensive domain experience. The SAB will be working closely with members of the Lykan Bioscience and RoslinCT management and scientific teams, providing valuable insight into a range of topics across the development and manufacturing of advanced therapies.
8th Sep 2022
HM Queen Elizabeth II (1926-2022)
We are saddened by the death of Her Majesty Queen Elizabeth II.
30th Aug 2022
aTen Therapeutics to develop new breast cancer treatment
aTen Therapeutics awarded £282k to develop new breast cancer treatment
8th Aug 2022
BioIVT Acquires Cypex, a Leading Manufacturer of Drug-metabolizing Enzymes
Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
4th Aug 2022
RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO
The RoslinCT-Lykan combination creates an innovative advanced therapies contract development and manufacturing organization (CDMO) with process and analytical development laboratories and cGMP manufacturing facilities located in Hopkinton, Massachusetts and Edinburgh, Scotland. The combined group will offer process development expertise and cGMP manufacturing for a broad range of autologous and allogeneic cell therapies, with unparalleled expertise in gene editing and industry-leading induced Pluripotent Stem Cell (iPSC) capabilities.
26th Jul 2022
SLA response to the Government consultation on future strategy for testing and release of medicines
For the SLA response to the Government consultation on future strategy for testing and release of imported medicines please click here.
22nd Jun 2022
Cyclacel Pharmaceuticals Elects Kenneth M. Ferguson, Ph.D. to Its Board of Directors
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders.
8th Jun 2022
RoslinCT continues its growth plans by expanding its operations at Edinburgh Technopole
Edinburgh, UK, 08 June 2022 – RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter– signs lease for 1,453 sqm additional space at Charles Darwin House at the Edinburgh Technopole.
8th Jun 2022
Tepnel: Establishment of Employee Ownership Trust
Tepnel, a Scottish Pharma Services Company, based in Livingston, Scotland, announces the completion of the sale of the business to Tepnel Life Sciences Trustees LImited.
11th Apr 2022
Life Sciences Start-up Report now available through WAPG
The report, written by Glen Crocker of both We are Pioneer Group and JLL is now available from the link here: https://www.wapg.co/reports/
8th Apr 2022
Medannex presents data on MDX-124
Medannex’s first-in-class agent shows significant activity against clinically challenging cancers
17th Mar 2022
Scottish biotech company ILC Therapeutics strengthens team to accelerate development of Covid19 drug
Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials. Company ready to accelerate the development of Alfacyte™ – ILC’s lead hybrid interferon designed to combat viral infections including Covid-19. ILC Therapeutics (ILC), a pioneer in the discovery and development of a ground-breaking class of interferon medicines designed to combat viral infections such as Covid-19, has announced that it has made two senior appointments.
8th Feb 2022
Scots pair partner on device to develop medicines and reduce antibiotic resistance
Two independent Scottish companies have come together to speed up the development of medicines, vaccines, and key ingredients for reducing antibiotic resistance.
21st Jan 2022
Medannex: monoclonal antibody MDX 124 highly active in pancreatic cancer models
Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models
12th Jan 2022
Apposite Capital-backed Kelso Pharma acquires Stirling Anglian Pharmaceuticals
PRESS RELEASE
10th Dec 2021
Medannex presents data on new therapy showing powerful synergy with common cancer treatments
Medannex’s new therapy shows powerful synergy with common cancer treatments
9th Dec 2021
103.5 million pounds raised by Ideagen Plc to bolster international growth plans
Leading global provider of information management software, Ideagen Plc, has today announced that it has raised £103.5 million to accelerate product investment and scale global operations through further acquisitions.
8th Dec 2021
NovaBiotics Announces First Patient Enrollment into the Cysteamine Domain of REMAP-CAP
NovaBiotics Announces First Patient Enrollment into the Cysteamine Domain of REMAP-CAP
17th Nov 2021
ResMed Invests in Lenus Health, Recent Winner of NHSX AI Health and Care Award
ResMed Invests in Lenus Health, Recent Winner of NHSX AI Health and Care Award
6th Sep 2021
ILC Therapeutics announces successful completion of 3.5M funding round
PRESS RELEASE (Issued on behalf of ILC Therapeutics)
17th Aug 2021
Alba Science joins Eurofins Scientific
Alba Science is pleased to announce that it has joined the Eurofins Scientific Group.
11th Aug 2021
Q2 Solutions Announces Significant Expansion of Laboratory Operations in Scotland, UK
For further details click here
10th Aug 2021
Valid Insight is joining the Bioscript group.
Valid Insight are delighted to announce that we are joining the Bioscript group.
29th Jun 2021
Cell and Gene Therapy Catapult to expand to Edinburgh BioQuarter
The Cell and Gene Therapy Catapult (CGT Catapult) today announces that it will establish offices and laboratories in Edinburgh, Scotland. With this expansion CGT Catapult aims to provide additional, regionally focused support to the cell and gene therapy sector to accelerate product development, clinical trials and adoption.
21st Jun 2021
NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial
NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia
16th Jun 2021
Storm ID awarded Artificial Intelligence in Health and Care Award by UK Government for innovative CO
Scottish digital transformation consultancy Storm ID has been successful in the latest round of the ‘Artificial Intelligence in Health and Care Award’, for a service which uses artificial intelligence to help patients with COPD (Chronic obstructive pulmonary disease).
1st Jun 2021
Novabiotics announces publication of NP339's Broad Antifungal Activity
NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy
24th May 2021
Quotient Limited Announces New $95 Million Financing Led by Highbridge
Quotient Limited Announces New $95 Million Financing Led by Highbridge
27th Apr 2021
BioCity Group has been acquired Trinity Investment Management and Harrison Street Real Estate Capita
10th Apr 2021
Medannex unveils the multiple anti-cancer effects of MDX-124
Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021.
26th Mar 2021
Medannex Life Sciences Annual Awards Scotland
For more information please click here.
15th Mar 2021
New backing accelerates Fixed Phage's fight against harmful bacteria
Pioneering UK biotechnology business, Fixed Phage, has secured additional investment to scale up its fight against new microbial threats that pose risks to human health and agricultural production.
15th Mar 2021
UK Government announces partnership with Omega Diagnostics
UK GOVERNMENT ANNOUNCES PARTNERSHIP WITH CLACKMANNANSHIRE RAPID TEST MANUFACTURER
5th Mar 2021
Medical Incubator Japan through Bamburgh Capital target further UK Healthcare investments in 2021
2nd Mar 2021
EY invests in growth of Life Sciences business
EY today announces that it has expanded its Life Sciences practice with the appointment of two new Partners, four Associate Partners and three Directors in the UK and globally. Over the last few months, EY has hired an additional 37 people, ranging from Consultant level to Senior Manager level, making it a leading commercial team in Europe.
26th Feb 2021
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
FOR IMMEDIATE RELEASE
23rd Feb 2021
Storm ID makes inroads into NHS Scotland
For the latest press releases from stormid please click the links below:
19th Jan 2021
NextPharma Set to Acquire the Lonza Livingston facility, Specialized in Lipid Oral Dosage Forms
NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms
11th Jan 2021
Intuitive Investment Group Investment in Light Science Technologies
Intuitive Investment Group(IIG) makes it first investment into Light Science Technologies. More info click here
31st Dec 2020
UK-EU TRADE AND COOPERATION AGREEMENT - Summary
For a summary of the BREXIT deal, please click here
14th Dec 2020
Intuitive Investments Group admitted onto AIM
David Evans' Intuitive Investments Group (IIG) has today been Admitted onto London’s AIM.
1st Dec 2020
ILC Therapeutics announces first international investment
UK biotech company ILC Therapeutics announces first international investment
19th Nov 2020
KKR to acquire animal health firm Argenta for about $100 million
KKR & Co Inc will buy a majority stake in animal health firm Argenta Limited, as the pet and animal care industry continues to draw private sector interest.
16th Nov 2020
Intelligent Tissue Group launches Clinical Trials Facility to Boost Global Operations
21st Oct 2020
Regulating Medical Devices from 1 January 2021
New Guidance, should the UK fail to achive a trade deal with the EU, has now been made available here.
16th Oct 2020
NovaBiotics Innovate UK COVID-19 grant award for Nylexa
NovaBiotics receives £1m Innovate UK grant to fund its COVID-19 Nylexa therapy programme.
13th Oct 2020
Nucana raises $80Million in follow on funding
NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar
12th Oct 2020
ILC Therapeutics COVID-19 Drug Breakthrough
ILC Therapeutics Announces ‘Significant’ COVID-19 Drug Breakthrough
18th Sep 2020
Safety-critical alerts are changing at the MHRA
Changes are being made to the way the Medicines and Healthcare products Regulatory Agency (MHRA) issues safety-critical alerts to healthcare providers.
1st Sep 2020
TUV SUD Measurement for Recovery Programme
TÜV SÜD National Engineering Laboratory (NEL), in collaboration with its partner UK measurement laboratories, is helping companies recover from COVID-19. The Measurement for Recovery (M4R) Programme, which is now open for applications, provides companies support to overcome measurement issues relating to their processes and/or products, etc. The scheme is aimed at non-off-the-shelf services and could cover up to a maximum of 20 days fully funded support from NEL. The £3m programme being led by NPL (National Physical Laboratory) will run until the end of March 2021. The process for applying is straightforward, requiring only the submission of two brief paragraphs explaining the problem, its impact and how the project will help the business recover from Covid-19. The project/product does not have to have any direct relationship to Covid-19, all that needs to be shown in the application is that due to the impact the pandemic has had on their business, the organisation has been unable to take it forward without the support of this Programme. The turnaround for decisions is only 3 working days. The scheme is intended to provide short, sharp interventions as opposed to funding longer-term R&D based projects. Therefore, the maximum project duration is expected to be around 2 months. Multiple applications are permitted providing these address different issues.
1st Sep 2020
Biotechnology sector expert bolsters Entrust growth
Executive search consultancy, Entrust, has announced the appointment of Mark Johnson as Senior Partner of its Oxford-based Global Healthcare arm.
1st Sep 2020
MHRA Update on MDR and IVDR
The MHRA has confirmed that, in a departure from the EU Withdrawal Agreement, the UK will now not be implementing the MDR and IVDR post the transition period. For further details please see here.
17th Aug 2020
MIJ Launches a New Biotech Fund in Partnership with Nippon Shinyaku and Torii Pharmaceutical
Bamburgh Capital Limited is pleased to announce that MIJ has secured commitments from two prestigious Japanese Pharmaceutical companies totalling 20 billion Yen, approximately 20 million dollars. Over the next twelve months, they intend to target a total fund of 50-60 million dollars. • Nippon Shinyaku is a prominent Japanese pharmaceutical company listed on the Tokyo stock exchange with a market capitalisation of $5.7 billion. They have both a pharmaceutical and nutraceutical division. • Torii Pharmaceutical is a prominent Japanese pharmaceutical company also listed on the Tokyo stock exchange with a market capitalisation just below $1 billion. It is a subsidiary of Japan Tobacco Inc which has a market capitalisation of approximately $40 billion. MIJ will provide support to accelerate commercialisation in Japanese markets including marketability evaluations, developing regulatory strategies, promoting clinical trials and introductions to experts and partners companies. In addition and if appropriate, MIJ will also be able to help companies explore licensing and other commercial agreements with Nippon Shinyaku and Torii Pharmaceuticals. Investment activity is expected to commence in early September 2020 and will broadly be focused on the areas of Pharmaceutical, Medical Devices and Digital Health. Further details of the fund can be found in the official press release.
17th Aug 2020
Cellexus begin growth drive
Dundee biotech, Cellexus, started on a growth drive this quarter with the addition of two new team members.
26th Jun 2020
RoslinCT announces the construction of a new Cell & Gene therapy manufacturing facility.
RoslinCT announces the construction of a new Cell & Gene therapy manufacturing facility.
23rd Jun 2020
Appointment Reflects Entrust Resource Solutions Growth Aim
Executive search consultancy, Horton International UK, has announced the appointment of scientific recruitment heavyweight, Dafydd Wright, as Managing Partner. The move comes as the company continues to implement the ambitious growth plans of parent group, Entrust Resource Solutions.
22nd Jun 2020
Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting
Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting
7th Jun 2020
Morningside Ventures to fund COVID19 Vaccine development
Full Press release here
19th May 2020
MGB Biopharma Announces Successful Outcome from Phase II Clinical Study
MGB Biopharma Announces Successful Outcome from Phase II Clinical Study with MGB-BP-3 – a Potential New Gold Standard, First-Line Treatment for Clostridium difficile Infection (CDI) Glasgow, Scotland, May 19th, 2020 – MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives, today announces that its Phase II clinical study has met its endpoints of safety, efficacy, and dose selection. The study confirms that MGB-BP-3, an antibacterial, has the potential to become the new gold standard, first-line treatment for CDI. The Phase II dose ranging study in patients with CDI showed that the 250mg of MGB-BP-3, given twice daily for 10 days, achieved an initial cure and sustained cure of 100%. This dosage regimen has now been confirmed for the next phase of clinical trials. Three dose levels were evaluated in the study, which was conducted at sites in the United States (US) and Canada. As reported previously, the drug showed better-than-expected efficacy at its lowest dose level (125mg given twice daily) and that trend was further improved, with maximum efficacy demonstrated at the second dose level (250mg given twice daily). The most important goal in developing a new medicine for the treatment of CDI is to prevent recurrent disease to provide a sustained cure. MGB-BP-3 achieves this goal by its unique rapid bactericidal activity, a feature shared by no other treatment available. At the 250mg dosed twice daily for 10 days, MGB-BP-3 recorded no disease recurrence measured at four weeks post-therapy. Recurrence is unacceptably high with current bacteriostatic treatments, occurring in up to one third of patients treated by current mainstay therapies. As in its Phase I study, MGB-BP-3 showed an excellent safety and tolerability profile with no serious adverse events (SAEs) reported in either study. Dr Thomas Louie, clinical professor at the Cumming School of Medicine at the University of Alberta, Calgary (Canada) and Principal Investigator of the trial, said: “C. difficile infection represents a major burden to the Canadian and US healthcare systems. A novel antibiotic that is able to kill this deadly pathogen before it is able to sporulate offers hope to patients and their families who suffer the pain and misery caused by this disease.” CDI is a serious and often life-threatening infection of the large intestine and is the most frequent cause of diarrhoea in hospitals and care homes. In the US alone, there are almost half a million cases every year associated with around 30,000 deaths; three people die of uncontrolled CDI each hour. CDI has been recognised as an urgent threat pathogen by the Centers for Disease Control and Prevention in the US and is a common consequence of antibiotic treatment in hospitalised patients. MGB-BP-3 has received Qualified Infectious Disease Product (QIDP) status from the FDA, enabling Fast Track submission and 5 years of extended marketing exclusivity. MGB-BP-3 will also be eligible to participate in the DISARM programme of prescribing incentives being considered in the US which will increase patient access to new and innovative treatments.
1st May 2020
Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA1
Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
22nd Apr 2020
R&D tax credits health check and cash grants information for members
During these times we understand cash flow is more critical to businesses right now than ever before. One area you may wish to consider is whether your current R&D tax credit claims are optimised and you are taking full advantage of the full benefit available to you. HMRC have recognised R&D tax credit claims may be critical to businesses cash flows during these times and they are putting in place plans to ensure the swift processing of payments.
25th Mar 2020
Coronavirus Fund Application Form now available in the members area
Please visit the members area for this and other forms related to COVID19
11th Mar 2020
RUA Medical has been acquired by AorTech International PLC,
RUA Medical is delighted to announce that it’s Founder, David Richmond has agreed to sell the company to AorTech International PLC, a company listed on the AIM market of the London Stock Exchange. As part of the deal, AorTech will change its name to RUA Life Sciences plc and David will become Chief Executive Officer of the enlarged group. RUA Medical will remain a full-service medical device subcontract manufacturer and will continue to serve its existing customers with the same people and facilities, and provide the quality of products and service previously enjoyed.
9th Mar 2020
Medannex announces new immunomodulatory approach to cancer treatment at Nature conference
For more information please click here and here.
5th Mar 2020
Calcivis PMA Approvable Letter
CALCIVIS receives Approvable Letter for its unique CALCIVIS® Imaging System from US FDA
30th Jan 2020
SLA members Green Cross Medico and GCU collaborate to boost clinical skills for nursing students
Veteran entrepreneur Gio Benedetti has kindly donated award-winning medical equipment to help boost the clinical skills of nursing students at Glasgow Caledonian University (GCU).
28th Jan 2020
EY Firepower Report 2020
The 2020 EY Firepower report is out now. 4 megadeals, worth a combined US$231b, shaped life sciences in 2019. Will the trend continue in 2020? Find out at: www.ey.com/firepower
16th Jan 2020
SLA members Charles River Laboratories and Fios Genomics form a Strategic Alliance
1st Nov 2019
Dr Stefan Symeonides to guide MedAnnex Phase I trial preparation
Dr Stefan Symeonides to guide MedAnnex’s Phase I trial preparation
8th Oct 2019
Cellexus go global with new distribution network
Biotech company, Cellexus International Ltd, have increased their distributor network to bring their CellMaker bioreactor range to a global market. The CellMaker range is now available from our distributor network: Lab Sweden and Lab Denmark, Nerliens Meszansky in Norway, MTB in Spain, Szabo Scandic in Austria and ProBio in Israel. We are also in discussions with a new distributor to cover Holland, Belgium and Luxemburg.
7th Oct 2019
MedAnnex begins cell line development at FUJIFILM Diosynth
For more information please click here.
25th Sep 2019
EY Pulse of the Industry 2019 Medtech report
For more information please press here.
12th Sep 2019
Sitekit launches new brand in digital identity
For more information please click here.
29th Aug 2019
11 million GBP boost for leading Scottish antibody company
MedAnnex press release
24th Jun 2019
Entrust Resource Solutions to grow their team
For more information please click here.
10th Jun 2019
Collagen Solutions - Appointment of Non-Executive Director
For more information please click here.
9th May 2019
Valid Insight Wins the Queen's Most Coveted Award for Enterprise
LONDON, April 22, 2019 /PRNewswire/ -- The Queen's Awards for Enterprise are the UK's most esteemed business awards, presented only to the most eminent of companies or individuals, demonstrating outstanding results in their field.
9th May 2019
Culzean to RUA name change
Information about Culzean to RUA name change can be found here
25th Apr 2019
Entrust Resource Solutions acquire second company
sla.scot/files/90116-250419-Press-Release-Entrust-Resource-Solutions-acquire-second-company.pdf
23rd Apr 2019
Tissue Solutions Ltd wins Queen's Award for Enterprise... Again!
Tissue Solutions Ltd, an award winning virtual biobank and tissue acquisition company that helps researchers ethically source biological materials, has won the prestigious Queen's Award for Enterprise in the International Trade category. Now in its 53rd year, these awards are announced on the Queen’s birthday and are one of the UK’s highest accolades recognising business achievement. It is the second time Tissue Solutions has been recognised for its excellence in International Trade, having also collected the award in 2014.
2nd Apr 2019
Canon Medical Celebrates Ten-Year Milestone of Cutting-Edge Research in Edinburgh
Canon Medical Research Europe Ltd. celebrates this month the ten-year anniversary of the acquisition of their company by its Japanese parent company in 2009. In that time, the organization has grown in scope from advanced imaging to include research in Artificial Intelligence (AI) and non-imaging healthcare data analysis and visualization, and integrated information management system development.
22nd Mar 2019
New EU Exit Publications
The Department for Business, Energy and Industrial Strategy has this week released guidance for businesses on placing manufactured goods on both the EU internal market and the UK market if the UK leaves the EU without a deal. This includes guidance covering the status of conformity assessment bodies, as well as promotional material to help businesses prepare. Other UK Government publications this week are as follows:
22nd Mar 2019
RoslinCT appoints David Bowie to Board of Directors
RoslinCT appoints David Bowie to Board of Directors
19th Mar 2019
Supplementary registrations guidance how to register your medical devices in a no deal scenario
The following additional guidance has been published as an updated, supplementary section to the Devices no deal guidance page.
13th Mar 2019
Reprocell join Medicines Discovery Catapult virtual R&D network
REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development
25th Feb 2019
US Trade Representative Signs Mutual Recognition Agreements with the United Kingdom
Some good news on pharmaceutical testing here.
22nd Feb 2019
How to prepare if the UK leaves the EU with no deal - more information
Recent UK Government publications are as follows:
21st Feb 2019
Data Protection if there is a no EU Exit deal
Please click here for the documentation.
18th Feb 2019
NovaBiotics Awarded 1.8m in Small Business Research Innovation-Innovate UK grant funding
NovaBiotics Awarded 1.8m in Small Business Research Innovation-Innovate UK grant funding to Advance its Antifungal Drug Candidate, Novamycin
12th Feb 2019
Home office - EU Settlement scheme
Information on the EU Settlement Scheme can be found here.
1st Feb 2019
How World Courier is preparing for Brexit
If you ship product into the EU then World Courier has provided a handy insight on how this could happen under differring scenarios. For more information please click here.
25th Jan 2019
Information on leaving the EU
Please find below links to recently published UK Government information to ensure businesses and citizens have the necessary information about how EU Exit will affect them and the practical steps they will need to take to be ready. The Home Office is using pilot phases to test the EU Settlement Scheme system and processes ahead of the public launch, due by 30 March 2019, and has published an employer toolkit this week. Other recent UKG publications are as follows: Geographical Indications (GI): creating UK schemes after EU exit Public-sector procurement under the EU Withdrawal Agreement
14th Jan 2019
Entrust Resource Solutions Embark on a Growth & Acquisition Strategy
Entrust Resource Solutions has launched an aggressive 5-year growth and acquisition strategy that will benefit our global customer base by enabling them to hire top talent while achieving the business growth necessary to reach our targeted £10 million turnover.
4th Jan 2019
Guidance note on the regulation of medicines,medical devices and clinical trials if there is no deal
Following the consultation on how medicines, medical devices and clinical trials would be regulated in a no-deal scenario, The UK Government has issued updated guidance setting out the UK’s proposed arrangements for regulation if we leave the EU on 29 March 2019 with no deal.
19th Dec 2018
The UK's future skills-based immigration system - consultation opens
The full paper and an excellent executive summary can be found here.
5th Dec 2018
uniQure incorporates novel synthetic promoter developed by Synpromics in new preclinical target
3rd Dec 2018
No-Deal Brexit could pose potential significant risk to Scottish NHS medicines budget
NEWS RELEASE
20th Nov 2018
New Branding Unveiled for Cellexus International
For full press release click here
20th Nov 2018
Fearsome Expansion
Media release: Leading product design consultancy, Fearsome, announces appointment
15th Nov 2018
Synpromics named among the top 50 fastest growing technology companies in the UK
Synpromics named among the top 50 fastest growing technology companies in the UK
15th Nov 2018
Update on Progress on the UKs exit from the European Union
The Prime Minister has confirmed that the Cabinet has agreed to support the draft text of the Withdrawal Agreement and outline of the political declaration on the future framework. This marks a decisive step forward, as the Cabinet has agreed in principle the terms of the UK’s smooth and orderly exit from the European Union and also the broad terms of our future relationship.
29th Oct 2018
Lamellar introduces its LAMELLASOME technology for the safe and effective delivery of nucleic acids
Glasgow, UK – 29 October 2018 - Lamellar Biomedical Limited (Lamellar), an innovative biotechnology company, pioneering new approaches for the safe and effective transfer of functional nucleic acids, announces that Dr Alec McLean ,CEO, Dr Lynsey Howard (Head of Preclinical) and Steven Porteous (Head of Clinical and Regulatory) will be attending BIO-Europe 2018 in Copenhagen to introduce potential partners and investors to its cutting-edge LAMELLASOME™ technology.
22nd Oct 2018
Sistemic Ltd. announce a milestone Global Service and License Agreement with Cynata Therapeutics Ltd
Glasgow, United Kingdom; 22nd October 2018:
18th Oct 2018
RoslinCT appoint Ian McCubbin OBE to Board of Directors
Full Press release here
17th Oct 2018
Synpromics Unveils Next Generation Liver Selective and Tunable Promoter Platform
10th Oct 2018
ROSLINCT and REPROCELL awarded 1.2 million stg project from Innovate UK for clinical-grade stem cell
Full press release here
4th Oct 2018
Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cy
BERKELEY HEIGHTS, N.J. and HOUSTON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC, Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, and The University of Texas MD Anderson Cancer Center today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.
19th Sep 2018
Tissue Solutions Ltd expands service offering with HistologiX Ltd. acquisition
Tissue Solutions Ltd expands service offering with HistologiX Ltd. acquisition
13th Sep 2018
How to prepare if the UK leaves the EU with no deal
For the latest no-deal papers on Brexit click here
10th Sep 2018
RGU launches new biomedical technology degree.
The rapidly developing and rewarding field of biomedical technology involves engineering, constructing and operating medical devices. Graduates can go on to work as engineers in the medical device industry, producing the next generation of devices such as prosthetics, through to specialists working in healthcare operating and maintaining equipment for diagnosis and treatment.
23rd Aug 2018
How to prepare if the UK leaves the EU with no deal
For the latest information click here
6th Aug 2018
Brexit Update - What the implementation period means for the life science sector
Some useful advice published today:
29th Jul 2018
Next in the LifeScience Effect interviews with Hugh Devine of Compliance Path now available
Go to www.thelifescienceeffect.com for ways to listen and subscribe.
9th Jul 2018
Dysis secures 17M stg to accelerate growth
Edinburgh – July 9th, 2018 – DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra colposcope used in cervical cancer screening, announces today the completion of an £18 million ($25 million) investment.
26th Jun 2018
David Venables wins the Disruptor category of EY Entrepreneur Of The Year 2018, Scotland
Edinburgh, UK, 22nd June 2018 / Sciad Newswire / Synpromics, the leader in gene control, is delighted to announce that David Venables, CEO of the Company, has won the ‘Disruptor’ category of Scotland’s EY Entrepreneur Of The Year 2018.
12th Jun 2018
Euan Cameron of Cohesion Medical interviewed as part of the recent Indiana mission.
Go to thelifescienceeffect.com for ways to listen and subscribe.
3rd May 2018
Synpromics Awarded 1.9m Grant from Scottish Enterprise
Edinburgh, UK, 3rd May 2018 / Sciad Newswire / Synpromics Ltd, the leader in gene control, today announced it has been awarded a £1.9m research and development grant from Scottish Enterprise. The funds will expand Synpromics’ world leading R&D programmes in gene regulation for cell and gene medicines.
25th Apr 2018
R&D funding for Canon Medical
£1.9m funding to Canon Medical for Research & Development Project.
24th Apr 2018
Sympromics awarded Innovate UK grant
Synpromics awarded Innovate UK grant to evaluate its inducible promoter platform in collaboration with Lonza Pharma & Biotech
16th Apr 2018
Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065
Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting Durable Mcl-1 suppression of at least 24 hours after a single dose of CYC065 BERKELEY HEIGHTS, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced results from a Phase 1 safety, pharmacokinetic and pharmacodynamic study of CYC065, the Company’s novel cyclin dependent kinase, or CDK2/9 inhibitor, in patients with advanced cancers. Data were reported at an oral presentation on Sunday, April 15, at 3:35 PM CT at the American Association for Cancer Research (AACR) Annual Meeting held in Chicago, IL.
10th Apr 2018
Jack Flanagan joins Rooney Nimmo
Jack Flanagan Joins Rooney Nimmo as Partner Adding Substantial Firepower to the Firm's Commercial Real Estate Practice
10th Apr 2018
Fixed Phage wins top award in Norway
Great news and well done to Jason Clark and team at Fixed Phage.
15th Mar 2018
MHRA's Data Integrity Guide published
The MHRA’s GXP data integrity guide has been published today.
14th Mar 2018
COHESION Medical Ltd wins FSB Employer of the Year Award
COHESION is thrilled to have won the Scotland Employer of the Year Award at the Federation of Small Business Award ceremony in Edinburgh. Euan Cameron (CEO), Sophie Hamilton (Product Design Engineer) and Rachel Garvey (Marketing Executive) represented the team at the FSB (Federation for Small Business) Celebrating Small Business Awards, held at the Playfair Library in Edinburgh.
12th Mar 2018
NovaBiotics' Lynovex receives Fast Track Designation for Cystic Fibrosis Exacerbations
Aberdeen, UK, 12 March 2018 - NovaBiotics Ltd (NovaBiotics), a clinical-stage anti-infectives biotechnology company, announces receipt of Fast Track Designation (FTD) for its cystic fibrosis (CF) therapy, Lynovex®, from the United States Food and Drug Administration (FDA).
21st Feb 2018
Positive Eight-Year Results of ChondroMimetic
21 February 2018 Collagen Solutions Plc (the "Company")
18th Dec 2017
Collagen Solutions Strengthens Board with Non-Executive Appointment
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds, and cardiovascular is pleased to announce the appointment of Chris Brinsmead CBE to the Non-Executive Board.
12th Dec 2017
Special SLA member training opportunity
The June HR SIG discussed training and leadership in particular. A point was made that while many individual members may not have enough people to fill a leadership programme, there was interest in members taking one or two places. Doreen Davidson spoke highly of their programme delivered by SLA member, Robertson Training. In particular, she highlighted the characteristics profiling aspects to better know yourself on the way to gaining more productive relationships with the people around you.
28th Nov 2017
NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award
NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award
31st Oct 2017
Capsugel Announces Expanded Capabilities for Clinical Trial Services at Edinburgh Facility
4th Oct 2017
Sistemic announce significant progress of pluripotent stem cell contamination in derived CT products
Sistemic announce significant progress of pluripotent stem cell contamination technology in derived cell therapy products
27th Sep 2017
NuCana plc Announces Pricing of Initial Public Offering
NuCana plc Announces Pricing of Initial Public Offering.
25th Sep 2017
Life Sciences Scotland Strategy: Conference, 21st November - SPECIAL RATE FOR SLA MEMBERS
15th Sep 2017
TGaS Advisors Teams with Mirador Analytics to Improve Forecasting to Biopharmaceutical Environment
/Click here to read full Press Release
29th Aug 2017
Aridhia and Great Ormond Street Hospital Sign Ten-Year Research and Innovation Platform Deal
Aridhia, the cloud-based data analysis platform provider, has agreed a new ten-year deal with Great Ormond Street Hospital NHS Foundation Trust (GOSH) which will see it deliver the research and innovation component of the Trust’s multi-year digital transformation programme.
21st Jul 2017
Cyclacel Announces Closing of $15.2 Million
Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) --
7th Jul 2017
Collagen Solutions Announces First Patient Enrolment in ChondroMimetic Clinical Study
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the commencement of patient enrolment into an open label extension study as part of the clinical development programme for ChondroMimetic®, an osteochondral scaffold for the repair of cartilage defects in the knee. CE-marking for ChondroMimetic® was previously achieved prior to the Company’s acquisition of the product and related IP, and this follow-up clinical study is a step towards reestablishing that CE-mark certification.
22nd Jun 2017
Sistemic Ltd Announce Innovate UK Grant to Develop Grounbreaking miRNA-based Assay
Sistemic awarded an Innovate UK grant to develop a groundbreaking, novel miRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products Glasgow, Scotland, 22th June 2017 Sistemic Ltd announced today the award of an Innovate UK grant to further develop, to a market-ready stage, its groundbreaking prototype microRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products. Sistemic will be partnered in this project by LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement. Cell therapies are seen as the future of treatment in a number of therapeutic areas including diabetes and cardiovascular disease and are expected to revolutionise medical care for a range of currently untreatable diseases. Cell therapies are increasingly using pluripotent stem cells (PSCs) to generate derived cell therapy products. However, PSCs, by their nature, have the potential to form tumours which raises concerns around PSC-derived cell product safety. Therefore, there is a need to demonstrate, sensitively, quickly and accurately, the level of contaminating pluripotent stem cells in a derived cell therapy product. Sistemic has developed a prototype product based around miRNA biomarkers to detect contaminating pluripotent stem cells in a derived cell therapy product in a simple, highly sensitive and rapid test format. This partnership will support Sistemic in order to further develop their prototype product and make it ready for the rapidly developing market in PSC-derived cell therapy products Sistemic will be supported by the UK’s innovation agency, Innovate UK, under “The Analysis for Innovators” grant.
13th Jun 2017
Collagen Solutions - Provisional Patent for Bone Graft Substitute Formulation Submitted
8th May 2017
Lamellar Biomedical Raises 5.75m in Series C Fund Raising Led by Invesco
Lamellar Biomedical Raises £5.75 million in Series C Fund Raising Led by Invesco
28th Apr 2017
SBRI Funding Competition: Clinical Decision Support In Emergency Care
SBRI funding competition: clinical decision support in emergency care From:Innovate UKPart of:Innovation grants for business: apply for funding, Business enterprise, and Research and innovation in health and social careFirst published:3 April 2017Last updated:10 April 2017, see all updates
27th Apr 2017
Dundee Cell Products Ltd. Rebrands as DC BIOSCIENCES Ltd
Please click here for the full press release
25th Apr 2017
Medical Research Scotland PhD Studentships - Call Open
MEDICAL RESEARCH SCOTLAND
19th Apr 2017
Synpromics Raises 5.2m of New Investment
Edinburgh, UK, 19th April 2017 / Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M.
6th Apr 2017
MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3
MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)
23rd Mar 2017
Opportunity to Hear David Evans Present 'A Chairman's Story' at UK Investor Show
23 March 2017
14th Mar 2017
Mirador Analytics Launches Online Version of Asset Evaluation Tool
Revolutionizing Asset Evaluation for Drug Development and Commercialization
22nd Feb 2017
Aridhia Wins 10-Year Deal with Great Ormond Street Hospital
Click here for full Press Release
15th Feb 2017
Collagen Solutions to Raise 12 million
SLA Member Collagen Solutions in £12m growth plan, see the press releases below for details:
1st Feb 2017
OncoBioPharm rebrands as 'aTen Therapeutics'
1 February 2017 OncoBioPharm Ltd is rebranded as aTen Therapeutics Ltd Scottish biotechnology company OncoBioPharm has announced that from today it will operate as aTen Therapeutics Ltd. aTen (pronounced ‘atten’) refers to the angiotensin pathway, which plays a key role in several major diseases, and is the target of the company’s lead antibody candidate, Tensinomab. The new name reflects the company’s commitment to exploring the full potential of its innovative technology platform, not only within oncology but across other major disease areas. Click here to read more
16th Jan 2017
NovaBiotics Announces First Patients Dosed in Lynovex Clinical Study
NovaBiotics announces first patients dosed in Lynovex clinical study
19th Dec 2016
SLA welcomes the 30% increase in revenues at Collagen Solutions
Collagen Solutions Plc - (the "Company" or the “Group”). Half Year Report : Interim Results for the six months ended 30 September 2016
6th Dec 2016
Lamellar Biomedical Completes Patient Recruitment for Clinical Study Assessing Visco-ease
Lamellar Biomedical Announces Completion of Patient Recruitment in the Pivotal Registration Clinical Study Assessing Visco-ease for the Treatment of Radiotherapy-Induced Xerostomia (RIX)
16th Nov 2016
DataVita Announces GxP Compliant Datacentre Hosting for Lifescience & Healthcare Sectors
DataVita, Scotland’s premier datacentre provider, has announced this week that the Fortis datacentre is now GxP compliant, creating a specialist offering for Life Science, Biotech and Healthcare organisations. It has selected CompliancePath, a specialist GxP consultancy, to deliver the compliance and validation services.
1st Nov 2016
Scottish biotechnology companies to chair expert panel session at Pharma Integrates
Dr Tina Flatau, Managing Director of innovative Edinburgh-based biotechnology companies OncoBioPharm Ltd and MedAnnex Ltd, has been invited to chair a panel session of experts at the 2016 Pharma Integrates conference at London’s Grange City Hotel later this month. Please click this link for the full press release.
8th Sep 2016
Arrayjet Secures £650k Funding to Accelerate Innovation
Click here to read articles regarding SLA member Arrayjet's record fumding round:
31st Aug 2016
SLA Response to Scottish Government Enterprise & Skills Review
Please click here to read the response from SLA to the SG Enterprise and Skills Review
22nd Aug 2016
Matthew Speers new CEO of the Life Sciences Organisation (LSO)
The Department for International Trade’s (DIT) Life Sciences Organisation (LSO) is pleased to confirm Matthew Speers as our new CEO, effective 22nd August 2016. Matthew will take over from Dr Mark Treherne who has led the organisation since 2012 helping, along with others, to attract more than 6 billion pounds in new investment and create more than 17,000 new jobs in the sector.
22nd Aug 2016
Aridhia's Data & Analytics Service Selected For Use In Landmark £6.9M Alzheimer's Study
Scottish informatics company Aridhia will be among a cohort of research organisations undertaking the world’s most in-depth study to better detect Alzheimer’s Dementia, aiming to identify early signs of the disease and improve our understanding of its progression.
18th Aug 2016
Edinburgh Napier Applied Science Graduate Careers Festival
Calling all Life, Sport and Social Science employers!
15th Aug 2016
NSF Medical Devices Training Courses - Discount for SLA Members
www.nsf.org/training-education/all-courses/category/training-medical-devices NSF Health Sciences would like to offer SLA members a 40% discount for each delegate reserving a place on any of their courses. The offer is limited to the first 10 places on a first come, first served basis and will only be valid until 26 August 2016. If you or any of your members wish to learn more about the content of the courses, please speak directly to the tutor, James Pink. James may be contacted on +44 (0) 7850 900679 or by email at jamespink@nsf.org
5th Aug 2016
NovaBiotics Commercial Collaboration Deal for (Oral) Lynovex®
NovaBiotics Ltd, the UK-based clinical-stage anti-infectives biotechnology company, today announced that it has entered into an agreement with an undisclosed global partner to commercialise Lynovex®, the Company’s first-in-class oral intervention for acute infectious exacerbations associated with cystic fibrosis (“CF”).
2nd Aug 2016
Omega Diagnostics Secures £1.8m R&D Grant
Omega Diagnostics has secured a Scottish Enterprise research and development grant of £1.8m. This represented a significant contribution towards the total R&D project costs to fund the planned expansion of the Company's Allersys range of reagents for use in allergy in vitro diagnostics. The project funding will be used to accelerate a growth in menu from 41 allergens to 120 allergens over the next three years to cope with anticipated increasing demand.
28th Jul 2016
Epidarex Capital Creates Nodthera Limited
Epidarex Capital Creates Nodthera Limited
16th Jun 2016
Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements
BERKELEY HEIGHTS, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today that it received notification from the Listing Qualifications Staff of NASDAQ that it has regained compliance with the minimum bid price rule for continued listing on The NASDAQ Capital Market. The notification stated that as of June 14, 2016, the Company has evidenced a closing per share bid price of its common stock in excess of NASDAQ's $1.00 minimum closing bid price requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5550(a)(2) and will continue to trade on The NASDAQ Capital Market.
14th Jun 2016
SLA Response to SFC Innovation Centre Consultation
The SLA exists to represent and promote the interests of the life sciences sector in Scotland. Scottish Government / SFC policies aimed at encouraging the sector’s competitiveness by enabling universities to help drive economic growth, and through better access to university research by businesses are issues of very great interest to our member companies, and so we are glad to have this opportunity to state our views on the important questions raised by this SFC consultation exercise. Click here to read in full the SLA response to the SFC Consultation on Innovation Centres
7th Jun 2016
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
27th May 2016
Aridhia Announces Expansion Following Six-Sigure Netherlands Contract
Click here for full article from Herald Scotland
19th May 2016
ProStrakan rebrands as Kyowa Kirin
ProStrakan, the Scotland-based specialty pharmaceutical company, has rebranded as Kyowa Kirin as from the 18th April 2016.
10th May 2016
New Funding Opportunity from Innovate UK
Businesses can apply for funding to support a range of innovation projects that tackle commercial challenges in manufacturing and materials.
10th May 2016
Roslin Stem Cell Companies Combine to Create Censo Biotechnologies Group.
Roslin stem cell companies combine to create Censo Biotechnologies group.
6th May 2016
Sistemic & Cynata announce cooperation on in-process purity assay development for CT product
Sistemic and Cynata announce cooperation on in-process purity assay development for Cell Therapy (CT) product. Sistemic Ltd. and Cynata Therapeutics Limited (ASX:CYP) announced today that they have entered into an agreement which will see Sistemic use its novel SistemQC™ miRNA technology platforms, together with its extensive internal databases of cellular products, to develop an in-process assessment assay for Cynata’s unique Cymerus™ Cell Therapy (CT) products. This follows an extensive period of feasibility assessment where Cynata evaluated the Sistemic technology portfolio and approach. The development of CT products represents a major breakthrough in the potential to treat a wide range of diseases which are currently untreatable. Nevertheless, the sector has many challenges, not least in terms of standardisation and scale-up. The combination of Sistemic’s predictive miRNA technology, with the standardised and highly scalable technology from Cynata, presents a potential winning combination and paves the way for rapid industrialisation of a wide range of CT products which could revolutionise the way a wide range of diseases are treated. Jim Reid, Chairman and CEO of Sistemic said “The CT industry holds much promise in so many ways for patients who have untreatable conditions, but the need for standardisation and industrialisation are big challenges the industry has not yet overcome. The combination of the technologies from two of the industry’s leading companies in trying to solve these scalability and reproducibility problems will undoubtedly enhance the speed of clinical development and subsequent uptake into clinical practice. By combining the strength of Sistemic’s technologies and understanding of the biology of cells together with the wide range of attributes of Cynata’s Cymerus technologies we see this collaboration as potentially transformational for the industry as a whole, and would represent a step change in the industrialisation of the sector.” Kilian Kelly, Vice President, Product Development at Cynata said “Cynata’s unique Cymerus technology delivers a process to manufacture a consistent therapeutic CT product. The development of robust, efficient and sensitive assays is a cornerstone of the development of such a therapeutic product, especially in view of its complex biological nature. Sistemic’s innovative SistemQC™ miRNA has a number of valuable attributes, and we expect this cooperation to help smooth the path forward for our Cymerus clinical development programs.”
21st Apr 2016
Quotient Awarded UK’s Highest Accolade for Business Success
Leader in the development and manufacture of transfusion diagnostic products awarded prestigious Queen's Award for outstanding achievement in international trade
19th Apr 2016
Tissue Solutions Ltd Among the First to Transition to the New ISO 9001:2015 Standard
Tissue Solutions, a global provider of human biomaterials for research, are proud to be one of the first companies in the UK to achieve certification to the 2015 version of the ISO 9001 Management standard. Tissue Solutions was independently assessed in January 2016, and achieved certification with no major non-conformances.
13th Apr 2016
Quotient Announces Achievement of Major MosaiQ™ Milestones & Preliminary Financial Results
• Initial Manufacturing System for MosaiQ™ Consumables Successfully Commissioned • First MosaiQ™ Field Trial Instruments Built and Received for Internal Evaluation Click here for full press release
13th Apr 2016
Quotient Announces Positive MosaiQ™ Serological Disease Screening Results
Click here for full press release
11th Apr 2016
Össur acquires Touch Bionics
Össur acquires Touch Bionics Apr 11th, 2016 Össur has today signed an agreement to acquire Touch Bionics Limited, a leading global provider of innovative upper limb prostheses and supporting services. Touch Bionics has over 120 employees with operations in Scotland, Germany, and the United States. In 2015, total sales amounted to GBP 15 million (USD 21 million) with an adjusted EBITDA of GBP 0.9 million (USD 1.3 million).
10th Mar 2016
Scotland Launches World Class Entrepreneurship Programme - Scotland Can Do SCALE
SCOTLAND LAUNCHES WORLD CLASS ENTREPRENEURSHIP PROGRAMME
2nd Feb 2016
Lamellar Biomedical - Visco-ease Paper Published in Supportive Care Journal
Visco-ease Paper Published in Supportive Care Journal
2nd Feb 2016
Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
1st Feb 2016
Aridhia data platform used in major £64m European research collaboration to tackle Alzheimer's
Aridhia’s data platform used in major £64m European research collaboration to tackle Alzheimer’s dementia
29th Jan 2016
My World of Work: careers web service launch
My World of Work: careers web service launch
28th Jan 2016
Roslin Cell Sciences relocates to larger premises at Roslin BioCentre
Roslin Cell Sciences relocates to larger premises at Roslin BioCentre
28th Jan 2016
Vascular Flow Technologies closes £10M financing round for strategic realignment
11th Jan 2016
Roslin Cells creates two commercially focused subsidiaries: Roslin Cell Therapies & Roslin
Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations. Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trial. Roslin Cell Sciences will focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.
11th Jan 2016
Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016
11th Jan 2016
Synpromics & CT Catapult announce joint project aimed at helping to commercialise gene therapy
11th Dec 2015
SLA Welcomes News that Quotient is to Develop New Manufacturing Facility Near Edinburgh
Quotient Limited Announces Plans for New Product Development and Manufacturing Facility Near Edinburgh, Scotland JERSEY, Channel Islands, December 9, 2015 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it has entered into a construction contract with MW High Tech Projects UK Limited for a new product development and manufacturing facility at the Midlothian Biocampus (the “Biocampus Site”) near Edinburgh, Scotland. The Contract provides for the first phase of the project, encompassing product manufacturing, which is expected to be completed by August 2017. The estimated cost of the first phase is approximately £15 million, or $23 million at current exchange rates, with funding expected to be provided primarily from the proceeds of a sale and leaseback transaction. Click here for the full Press Release
9th Dec 2015
AGTC and Synpromics Limited Announce R&D Collaboration
AGTC and Synpromics Ltd Announce R&D Collaboration to Develop Synthetic Promoters for Enhanced Gene Therapy Candidates
1st Dec 2015
Biopta to be acquired by Japanese stem cell company ReproCELL
The Japanese regenerative medicine company ReproCELL Inc., has announced the acquisition of the Scottish life sciences company, Biopta. The acquisition of Biopta and its US subsidiary, Biopta Inc. is expected to complete on the 10th of December and is aimed at strengthening ReproCELL’s pharmaceutical industry-targeted drug discovery services. The acquisition will also see an immediate investment to expand Biopta’s range of contract research services. Biopta, which will continue to operate from its headquarters in Glasgow, aims to grow its workforce to 30 over the next three years and Biopta’s management views the synergies within the ReproCELL Group of companies as key to its growth ambitions. Dr David Bunton, Biopta’s co-founder and CEO said, “The acquisition by ReproCELL is a great opportunity to build on the solid platform we have in outsourced drug discovery services. Scotland is known for the quality of its scientists and customer service and ReproCELL’s investment recognizes these strengths. We have had a close partnership with BioServe, another ReproCELL Group company, for the past five years, which has helped us establish a very successful US subsidiary. We see the acquisition as the natural next step in the growth of the UK and US businesses.” ReproCELL, a leader in the field of stem cells and regenerative medicine, was established in 2003 with the goal of contributing to people’s health and welfare through the development of stem cell technologies. Many of ReproCELL’s technologies were developed by the stem cell pioneers, Prof. Norio Nakatsuji from the Institute for Integrated Cell-Material Sciences, Kyoto University, and Prof. Hiromitsu Nakauchi from The Institute of Medical Sciences, The University of Tokyo. ReproCELL’s CEO, Dr Chikafumi Yokoyama said of the acquisition, “This will allow our company to increase our market share by expanding our lineup of drug discovery support products aimed at the pharmaceutical industry and accelerate the development of ReproCELL’s new products and services.”
19th Nov 2015
New Website for SLA Member PACLA MEDICAL
Currently, PACLA MEDICAL is working on development of an automated physiotherapy device which will be used to improve the symptoms of walking difficulty, neck and back pain, in Multiple Sclerosis (MS) and chronic back pain conditions. Click the link below to access the new company website:
18th Nov 2015
Collagen Solutions - Appointment of Chief Business Officer
The Board of Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the appointment of Jamal Rushdy as Chief Business Officer with immediate effect.
16th Nov 2015
Interview with Alec McLean, Lamellar Biomedical Ltd
Mike Ward, global director of content for Informa Pharma Insights, chats with Lamellar Biomedical Ltd's CEO Dr. Alec McLean at the recent BIO-Europe partnering meeting in Munich, Germany, about the firm's R&D plans for recently raised funds and progress of Lamellar's cystic fibrosis program. Interview available at link below:
22nd Oct 2015
Vascular Flow Technologies launches Spiral Flow™ PV Bypass Graft registry in Germany
12th Oct 2015
Edgar Stewart launches dedicated recruitment service for high-growth start-ups and SMEs - Talented
Edgar Stewart launches Scotland’s first and only dedicated recruitment service for high-growth start-ups and SMEs – Talented.
9th Oct 2015
Roslin Cells' Retinal Pigment Epithelial (RPE) Cells Used in Clinical Trial
The First Patient In A Clinical Trial Receives Investigational Treatment For 'Wet' Age-Related Macular Degeneration (AMD) Using Retinal Pigment Epithelial (RPE) Cells Manufactured By Roslin Cells Edinburgh, Scotland, 09th October 2015
30th Aug 2015
Renishaw Diagnostics' new assay could revolutionise treatment of life-threatening disease
August 2015 – for immediate release Further information: Jim Greaves, +44 1415 577933
29th Aug 2015
Collagen Solutions To Work On Parkinson's Disease Research Project
Click for more information in The Scotsman article and LSE - Alliance News
25th Aug 2015
Edgar Stewart pledges investment in Scottish recruitment start-ups
Click the link to read the Edgar Stewart Press Release
5th Aug 2015
Point One Clinic to Open Weekly Clinic in Keith for MS Sufferers
Click on the link for the article in Banffshire Herald
30th Jul 2015
Capusugel expands in Livingston
Capsugel is expanding the Pharmaceutical Product Development and Manufacturing Capabilities at its Edinburgh Facility.
27th Jul 2015
Proposed acquisition of Select Pharma Laboratories by Source BioScience
Source BioScience plc (‘Source BioScience’, the ‘Company’) PROPOSED ACQUISITION OF SELECT PHARMA LABORATORIES LTD
24th Jul 2015
Lamellar Biomedical Closes £2.3 million Investment Round
Lamellar Biomedical Closes £2.3 million Investment Round
21st Jul 2015
MGB Biopharma commences Phase I clinical trial
MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections. For press release please click here.
20th Jul 2015
2015 MRS Sponsored Daphne Jackson Fellowships - Call Open
Daphne Jackson Fellowships - Call Open Up to three of these unique awards are again being offered by Medical Research Scotland.
7th Jul 2015
Vascular Flow expands global patent landscape with three new patents in Japan, China and Europe
24th Jun 2015
Calcivis Raises £4.5m to Drive Development of the Calcivis® Caries Activity Imaging System
Calcivis Raises £4.5m to Drive Development of the Calcivis® Caries Activity Imaging System Through to Commercialisation
17th Jun 2015
Vascular Flow announces collaboration with Society for Vascular Surgery® PSO
12th Jun 2015
NovaBiotics' Cystic Fibrosis Treatment Lynovex - Clinical Trial Data Presented
9th Jun 2015
SLA Members NovaBiotics, MGB Biopharma and Lamellar join in BEAM Alliance Launch
LAUNCH OF THE BEAM ALLIANCE – EUROPES’ COMBINED ACTION AGAINST ANTIMICROBIAL RESISTANCE
19th May 2015
Sistemic announces expansion of patent portfolio covering stem cell characterisation technologies
Glasgow, UK, Sistemic Limited (Sistemic), the miRNA profiling company with headquarters in Glasgow, Scotland, announced today the expansion of its granted patent portfolio in both the European Union and in the USA.
19th May 2015
Innovate UK Life Sciences Competitions - Register & Apply now
Click on the links for further information and registration details regarding the two Innovate UK competitions which have just opened:
15th May 2015
MGB welcomes O'Neill Report findings on antibiotics
Glasgow, Scotland, 15th May 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, endorses the latest report from Jim O’Neill’s Review on Antimicrobial Resistance and welcomes the idea of a global AMR Innovation fund.
5th May 2015
HRA announces 11 May as start date for phased roll out of HRA Approval
HRA announces 11 May as start date for phased roll out of HRA Approval
16th Apr 2015
Clyde Biosciences Announces £2m 'Series A' Investment
A UNIVERSITY of Glasgow spin-out behind pioneering technology to evaluate drug toxicity and improve patient safety has been boosted by a £2 million investment.
16th Mar 2015
Sistemic announce the initiation of ground breaking exosome research in Cell Therapy
Sistemic announce the initiation of ground breaking exosome research in Cell Therapy following grant award by Scottish Enterprise
10th Mar 2015
Craneware Partnership with Aridhia Informatics is Announced
Click on the link for Scotsman Article - Craneware inks Aridhia tie-up as profits rise 10%
4th Mar 2015
Vascular Flow Technologies signs deal with Vascutek to strengthen presence in Europe
4th Feb 2015
Vascular Flow Technologies announces appointment of Dr Barbara Bunger as Chief Clinical Officer
29th Jan 2015
MRS Funding for MS Study into Physiotherapy Technique
SCIENTISTS have been granted funding to evaluate the the benefits of an innovative physiotherapy technique for treating multiple sclerosis sufferers.
20th Jan 2015
Vascular Flow Technologies announces new Haemodialysis Access study funded by SE Grant
19th Jan 2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
14th Jan 2015
Life Sciences Scotsman Conference Discount for SLA Members
Life Sciences in Scotland: Realising the Manufacturing Potential
8th Jan 2015
New Board at Edgar Stewart Selection Aiming to Support Growth in Technology SMEs
Click on the link to read full Press Release - Edgar Stewart New Board Appointments January 2015
6th Jan 2015
Collagen Solutions to supply collagen powder to Globus Medical Inc
Collagen Solutions to supply collagen powder to Globus Medical Inc
24th Dec 2014
Collagen Solutions Signs Soluble Collagen Deal with Desu Medical
Click here for link to Herald Article 23 12 14
16th Dec 2014
Collagen Solutions Signs Wound Management Deal With Kyeron Medical
Collagen Solutions Press Release - Link to Herald Article
1st Dec 2014
NuCana appoints Dr. Paolo Paoletti to its Board of Directors
Link to Press Release - NuCana Board Appointment of Paolo Paoletti
24th Nov 2014
Vascular Flow Technologies data presented at VEITH Symposium
Data presented by Vascular Flow Technologies at VEITH Symposium shows 30% increase in one-year success rates for vascular bypass surgery, and dramatic reduction in amputations. Link to full press release here
21st Nov 2014
Collagen Solutions plc to acquire Southern Lights Biomaterials
Liink to Collagen Solutions announcement regarding intended Acquistion of Southern Lights
17th Nov 2014
SLA Welcomes Daily Record Article on MS Sufferer's Positive Experience of Point One Clinic
Link to Daily Record Article describing Aileen McAusland's experience of Point One Clinic
13th Nov 2014
Royal College of Paediatrics and Child Health endorses Sitekit eRedbook
Great news from SLA member Sitekit Solutions - after three years of intense development and testing, its eRedbook has this week received the clinical endorsement required for it to be offered to the NHS market in England.
11th Nov 2014
SLA Evidence to Scottish Government on Uni/Business Issues
SLA evidence to LiSAB hearing on university/ndustry issues
29th Oct 2014
ARIDHIA JOINS THE GLOBAL ALLIANCE FOR GENOMICS AND HEALTH
Link to Aridhia Press Release
16th Oct 2014
Carnegie Trust: Collaborative Research Grants Call for Proposals
The Carnegie Trust for the Universities of Scotland invites applications for innovative research projects under its Collaborative Research Grants scheme. Proposed projects must:
8th Oct 2014
Sistemic & TC BioPharm Announce Collaboration to Develop Cancer-Specific Theranostic Products
Link to press release: TC BioPharm & Sistemic cancer biomarkers
7th Oct 2014
NovaBiotics’ Dr Deborah O’Neil Named EY UK Health Products & Services Entrepreneur of 2014
Link to NovaBiotics Press Release
7th Oct 2014
Company Placements Wanted for Star Students
What is the Life Science Employability Programme? Further information available here
30th Sep 2014
Optos in £1.1 million collaboration with NHS Greater Glasgow and Clyde
Major funding announced to develop new technology to detect sight threatening disease
26th Sep 2014
Tissue Solutions Receives Queen’s Award for Enterprise
Link to Press Release - Tissue Solutions Receives Queen's Award for Enterprise
22nd Sep 2014
Merck KGaA to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry
Link to Merck and Sigma-Aldrich press release
17th Sep 2014
MGB Biopharma Secures £4m to Advance Novel Lead Antibacterial into Clinical Development
Link to MGB Biopharma Press Release
16th Sep 2014
NovaBiotics Receives Orphan Drug Status from FDA for Lynovex® for Treatment of Cystic Fibrosis
Link to NovaBiotics Press Release
8th Sep 2014
Harvard University Receives Transformational Gift From Chan Family
Harvard University Receives Transformational Gift for the School of Public Health
28th Aug 2014
Patheon Parent Company, DPx Holdings, Acquires Gallus BioPharmaceuticals
Link to News Article
27th Aug 2014
Sunday Herald - Is there life in our science industry?
Link to Sunday Hearld Article on Life Sciences in Scotland
28th Jul 2014
Gael team up with Compliance Path to offer complete validation service
Compliance Path partnership - press release
28th Jul 2014
Axis-Shield announces launch of new HbA1c assay
Link to Axis-Shield E-Newsletter
22nd Jul 2014
SLA welcomes the UK Government investment in Scottish life sciences
Scott Johnstone, Chief Executive of the Scottish Lifesciences Association, welcomed the announcement made by the Chancellor today of UK Government investment in Scottish life sciences. He said:-
11th Jul 2014
Prostrakan Announces Acquisition of Archimedes
Scott Johnstone, Chief Executive of the Scvottish Lifesciences Association, said "We welcome today's news that Borders-based ProStrakan has agreed to acquire Archimedes Pharma. This is further evidence of Scotland's ability to develop globally successful life sciences businesses, and of the growing importance of this vibrant sector to the Scottish economy. The track record of Scottish life sciences companies developing and offering innovative products and therapies speaks for itself, and we congratulate ProStrakan – and Archimedes – on this deal."
25th Jun 2014
BioOutsource Plans to open a US Lab Facility in Massachusetts in 2015
Business growth - US expansion Press release
23rd Jun 2014
NovaBiotics’ Dr Deborah O’Neil Named EY Scotland Entrepreneur of 2014
NovaBiotics’ and SLA Board Member Dr Deborah O’Neil has been named EY Scotland Entrepreneur of 2014. Click here for the press release
9th Jun 2014
Congratulation to MGB Pharma on TSB Success
SLA welcomes MGB Pharma's recent TSB award.
5th Jun 2014
NHS Launches Health & Social Care Innovation Fund
Click here for the NHS Press Release
2nd Jun 2014
NuCana's Acelarin Achieves High Disease Control Rate in Patients with Advanced Cancer
www.nucanabiomed.com/downloads/NuCanaASCO2014.pdf
29th May 2014
Epidarex Capital Raises Fund to Make Significant Investments in Early-stage UK Life Sciences
Follow the link to the Epidarex website Epidarex Capital, a leading international venture capital firm, has raised over £47.5 million to lead investments in early-stage life science and health technology companies, including spin-outs from leading research universities.
26th May 2014
3 Places Left on Records Management Training Programme. 10% Discount!
Russell Joyce & Eldin Rammell have created a records management training programme designed specifically for records managers, archivists, document administrators and related roles in the Life Sciences sector aimed at those who have limited experience in the field, for example new staff working in a GLP archive or as a TMF administrator. We shall be delivering the first module in that programme “Introduction to Records Management and Archiving” on Thursday 12th June 2014.
19th May 2014
Professor Robert Brown joins Collagen Solutions as Scientific Adviser
Click on the link for the full press release on Collagen Solutions website: www.collagensolutions.com/content/investors/2014/190514.asp
1st May 2014
Quotient Prices Initial Public Offering
Link to Press Release www.quotientbd.com/news/quotient-limited-prices-initial-public-offering
1st May 2014
Global Exposure for Touch Bionics
userfiles/140501 - UKTI Touch Bionics OMIS case study.pdf
21st Apr 2014
Tissue Solutions Wins Queen's Award for International Trade
Tissue Solutions press release
10th Apr 2014
SLA Welcomes Scotland's largest private investment into Nucana
The SLA is delighted to see this, the largest single private investment in a Lifesciences company in Scotland ever. It is a testament to Hugh and his team at Nucana and proves that a Scottish based company can raise substantial funds, internationally, in a key sector of the Scottish economy.
7th Apr 2014
SDS Funded Lab Skills Course to be Delivered by Edinburgh Napier
Life Science Opportunities
27th Mar 2014
Tissue Solutions Announces Appointment of Morag McFarlane as CEO
Click here for Tissue Solutions press release
24th Mar 2014
Introducing DPx Holdings B.V.
SLA member, Patheon, is one of three business units to make up DPx Holdings B.V. which was formed as part of a $2.6 billion transaction between JLL Partners and Royal DSM in March 2014. Click below for more information, and a video link:
24th Mar 2014
BioOutsource Launches Flagship Reverse Signalling Apoptosis Bioassay
BioOutsource - Reverse Apoptosis Bioassay Press Release and Webinar
21st Mar 2014
2014 Regenerative Medicine + Cell Therapy competition
The Technology Strategy Board Regenerative Medicines and Cell Therapies competition went live last week.
17th Mar 2014
Biomedical Catalyst Competition - Registration closes: 28 May 2014
Register and apply for Biomedical Catalyst Competition
17th Mar 2014
Competition for Single-Company and Collaborative R&D Funding June 2014
The call document for "Advancing Regenerative Medicines and Cell Therapies COMPETITION FOR SINGLE-COMPANY AND COLLABORATIVE R&D FUNDING JUNE 2014" is now available for download here
13th Mar 2014
Growth and Investment for Leading Entrust Clinical Team
Entrust Clinical Press Release
13th Mar 2014
New Improved TalentScotland website now live
The new, improved TalentScotland is now live, see www.talentscotland.com and the life sciences proposition is at http://www.talentscotland.com/science
13th Mar 2014
Scottish Patent Court under planned Unified Patent Court System
Litigation actions under the forthcoming Unitary EU Patent could be raised before the Scottish Courts following an amendment to the Intellectual Property Bill as it underwent its third reading before the Westminster Parliament. The changes to the Bill serve to include The Court of Session in Edinburgh as one of 4 possible UK Divisional Courts in which the forthcoming Unitary EU Patents could be litigated. The changes to the Bill will be enacted provided that suitable demand for such a forum can be shown. The inclusion of the Court of Session resulted from lobbying led by the Law Society for Scotland and Scottish MPs, both of which welcomed the amendment on the grounds that it provides greater choice to Scottish businesses.
10th Mar 2014
Derwentside Environmental take lab space at BioCity Scotland
BioCity Press Release
18th Feb 2014
A Global Leader in ADC Characterisation, BioOutsource, Partners With Glythera
BioOutsource - Glythera Partnership press release
7th Feb 2014
Epidarex Capital Leads New Investment in Edinburgh Molecular Imaging, a Pioneering Imaging Start-Up
Epidarex Capital press release
6th Feb 2014
MODE receives CE mark for home bowel-screening test and completes significant financing round
MODE Diagnostics Ltd Receives approval to commence sales of its digital home-use bowel-screening test; successfully completes significant financing round
5th Feb 2014
Roslin Cells launches the first Research Grade iPS cell bank
SLA welcomes the launch of the EBiSC project which will establish a central repository for research grade iPS cells in Europe. This is a collaboration of 26 partners with a headline value of €35 million and has been a major focus for Roslin Cells since late 2012.
5th Feb 2014
BioOutsource To Open New Biosimilar Centre of Excellence in Glasgow as Global Demand Surges
Link to BioOutsource press release
21st Jan 2014
Touch Bionics Reports Surge In Sales
Link to BBC News Article on 23% revenue growth achieved by Touch Bionics
17th Dec 2013
Encap Drug Delivery Announces Collaboration With Lipocine Inc.
Encap Lipocine Press Release
17th Dec 2013
Angel’s fall fuels biotech’s return to market
Scotsman Article on Collbio and the takeover of Collagen Solutions
11th Dec 2013
£3m Dementia Consortium unites MRC Technology with Alzheimer's Research UK
£3m Dementia Consortium launched to boost dementia drug discovery
10th Dec 2013
Healthcare Investment Opportunities acquisition of Collbio, Change of name to Collagen Solutions
Proposed Acquisition of Collbio Limited
9th Dec 2013
Tissue Solutions Pass Assessment Audit For ISO 9001 With BSI
Tissue Solutions is pleased to have passed their annual continual assessment audit for ISO 9001 with BSI on the 5th December 2013, demonstrating a commitment to continually improving our quality and management systems.
27th Nov 2013
UWI named Most Innovative Business at WeDO awards
WeDO Awards Celebrate Scotland's Entrepreneurs
5th Nov 2013
Irvine an opportunity as Scotland bids to grow life sciences
Irvine an opportunity as Scotland bids to grow life sciences
23rd Oct 2013
European Approval of Ferring’s Removable Misoprostol Vaginal Delivery System, MISODEL
European Approval of Ferring's Removable Mioprostol Vaginal Delivery Syste - MISODEL
21st Oct 2013
Scotland demonstrates its collaborative approach to cell therapy development
Collaborations with Roslin Cells and QCMD set to give Sistemic lead in cell characterisation standardisation and make Scotland key destination for cell therapy clinical trials
21st Oct 2013
Sistemic and QCMD announce innovative collaboration in cell therapy field
Sistemic Ltd and QCMD Ltd (Quality Control for Molecular Diagnostics) announced today that the companies had entered into a cross-licensing agreement. The arrangement centres on Sistemic’s SistemQC™ technology which is widely used by companies developing cell-based therapies allowing characterisation of the cell products and development of potency assays for product release and QCMD’s proprietary informatics platform and characterised quality assurance materials.
9th Oct 2013
Swinney Welcomes Life Sciences Growth and Praises New Business/NHS Partnership
Health Innovation Partnership News Release - 9 October 2013
3rd Oct 2013
Dow AgroSciences and Synpromics Announce R&D Collaboration
Synpromics Agreement News Release
25th Sep 2013
Onorach Unveils China Plans
Click on the link to find out more: us2.campaign-archive2.com/
19th Sep 2013
Cell Therapy Catapult & Roslin Cells to create clinical grade stem cells to accelerate research
Cell Therapy Catapult and Roslin Cells Press Release
28th Aug 2013
Onorach Introduce Clinical Trial Supplies
Onorach Introduce Clinical Trial Supplies
28th Aug 2013
NovaBiotics Enters into Agreement with Taro
NovaBiotics Taro License Agreement
27th Aug 2013
Aridhia and Peter MacCallum Cancer Centre collaborating on patient monitoring solution
Cancer Patient Monitoring -AridhiaPressRelease
25th Jul 2013
SLA Welcomes News Of £600k Further Funding Round For MGB Biopharma
Click on the link to read more about the £600,000 investment round completed by MGB Biopharma Ltd, the Glasgow based biotechnology company working on a new class of antibacterials: http://www.mgb-biopharma.com/news.html
18th Jul 2013
Lamellar Biomedical gains ISO 13485:2003 certification
Lamellar Biomedical was pleased to achieve ISO 13485:2003 accreditation. Great news to secure this in such a short time.
17th Jul 2013
Tissue Solutions New Client Services Team
Tissue Solutions New Client Services Team
4th Jul 2013
Smart Idea Store Launches Business Networking website for Innovation
A Scottish start-up company are looking for innovative lifesciences companies, investors ( business angels and VC firms) and project partners to participate in a free 3 month pilot of their website Smart Idea Store.
24th Jun 2013
SLA welcomes greater certainty provided by US Supreme Court decision
Gordon Stark, Chair of the SLA's Innovation SIG and COO with Murgitroyd and Co, said that the long awaited decision on the patentability of gene sequencing has now been taken. Click on the link to read more: http://bit.ly/141AKcN
17th Jun 2013
Tissue Solutions appoint new Business Development Director
Tissue Solutions Strengthen their Business Development Team
11th Jun 2013
Moredun Makes Major Breakthrough in the War Against Worms
Scientists at the world renowned Moredun Research Institute in Scotland, have made a major breakthrough in the battle to prevent and control parasitic worm infections by successfully protecting sheep using vaccination. The team at Moredun have recently had their results published in the leading scientific journal Vaccine1 and the paper reports the most successful attempt yet to protect animals against worms, using a laboratory produced vaccine, giving hope for a sustainable control strategy that does not rely on drugs.
10th Jun 2013
The SLA welcomes the news that Collbio Ltd has raised £250K to further develop collagen sales
Collbio, a new company set up in March this year by leading life science financiers Diagnostic Capital Ltd, together with former senior management team members Stewart White and Ross Andrews is pleased to announce the completion of an initial fundraising in excess of £250,000 from a number of private investors. The new funds will primarily be used for working capital to enable the business to generate revenue via the provision of collagen raw materials and contract manufacturing services.
6th Jun 2013
Fios Genomics Secures Second Funding Round
Fios Genomics Investment_Press Release
4th Jun 2013
Encouraging results from the ProGem1 study of NUC-1031 presented at ASCO 2013
http://www.nucanabiomed.com/downloads/ASCO2013.pdf
3rd Jun 2013
Deadline for Medical Research Scotland PhDs Announced
The closing date of Monday 15th July 2013 at 12 noon has been announced for all applications for up to 10 Medical Research Scotland PhD Studentship Awards. Click on the following link for more information, and to download all the documents needed to make an application: http://www.medicalresearchscotland.org.uk/apply.htm
7th May 2013
Aridhia and Life Technologies announced as lead commercial partners in SMS-IC
PressRelease_Stratified Medicine Scotland Innovation Centre
6th May 2013
Moredun and Fish Vet Group working together to develop novel vaccines for Aquaculture
Moredun and Fish Vet Group working together to develop novel vaccines for Aquaculture
6th May 2013
Aridhia - Strategic partnership signals new age of stratified medicine
AridhiaPressRelease
23rd Apr 2013
BioOutsource opens new facility in Cambridge, Massachusetts
Link to the press release
17th Apr 2013
Moredun Collaborate on EU Project to Improve Safety of Drinking Water
Moredun Press Release
15th Apr 2013
Touch Bionics i-limb controlled by new mobile app
http://www.bbc.co.uk/news/uk-scotland-scotland-business-22116083
18th Mar 2013
Colbio purchases assets of Angel Biomedical and secures major contract
Collbio Limited purchases assets of Angel Biomedical and secures major contract
14th Mar 2013
Sistemic and Progenitor Cell Therapy initiate study on stem cell characterisation technology
Sistemic and PCT press release
4th Mar 2013
SLA welcomes the acquisition of Encap Drug Delivery by Capsugel
Capsugel Announces Acquisition of Encap Drug Delivery
28th Feb 2013
Alba Bioscience Raises $5 Million of Growth Finance
Additional Quotient Biodiagnostics/Alba Bioscience Fundraising
11th Feb 2013
Anacail bringing to market new product which taps plasma power to protect products & people
Anacail news release
7th Feb 2013
BioCity Scotland set to be the UK centre for major new drug discovery initiative
IMI Announcement
6th Feb 2013
SLA welcomes Government data showing strong growth in Scottish life sciences employment
SLA News Release welcoming Scottish Government data on life sciences employment growth
28th Jan 2013
Win tickets and assistance to attend BIO 2013
Please click on the link to find out about UKTI's offer of a Partnering Pass to the 2013 Bio International Convention (22nd - 25th April, Chicago) and assistance with accomodation and flight costs: UKTI BIO Innovation Flyer
24th Jan 2013
Achieving compliance to ISO 13485 - Barriers to success & overcoming them
Achieving compliance to ISO 13485 - Barriers to success & overcoming them
22nd Jan 2013
SLA welcomes Rock Spring Ventures £50m venture capital fund
RSV press release
8th Jan 2013
Scottish company Lamellar Biomedical raises £3.3 million from Institutional investors
Edinburgh, 7 January 2013: Lamellar Biomedical is pleased to announce that it has raised £3.3 million in equity financing from existing and new shareholders including Barwell, Scottish Enterprise and TRI Cap angel investors. Funds managed by Invesco Perpetual form the core of the new shareholding. The proceeds of the offering will be used to further develop the Company’s lead product, LMS-611. The company has been advised by a Notified Body that LMS-611 will be regulated as a class 2b medical device for the treatment of dry eye disease (DED) and Radiotherapy Induced Xerostomia (RIX), commonly known as dry mouth. Lamellar Biomedical has been successful in forging strong links with the Scottish clinical community and is pleased to be working with the Vision Sciences Unit at Glasgow Caledonian University and the Beatson West of Scotland Cancer Centre respectively in these development programs. Additionally Lamellar Biomedical is progressing with a clinical program to investigate the role of LMS-611 as a medicinal product in cystic fibrosis. This program is being led by the West of Scotland Cystic Fibrosis unit led by Dr Steve Bicknell and Dr Gordon MacGregor. On the research front Lamellar has been successful in applying for three PhD studentships which will be held at the Roslin Institute and the Universities of Glasgow and Strathclyde. Following the completion of the financing Dr Duncan Moore has been elected as Chairman of the Company. Duncan Moore is a Partner at East West Capital Partners and was previously Global Head of healthcare equity research at Morgan Stanley. About Lamellar Lamellar Biomedical Ltd was established in June 2007 when the founding Directors of the Company, recognising the considerable therapeutic potential of Lamellasomes™, acquired the intellectual property rights to the technology. The Company benefits from an entrepreneurial Board of Directors and Management Team, a Scientific Advisory Board of eminent scientists and a Research Team with intimate knowledge of lamellar body physiology and pathology. Contacts: Dr Alec McLean CEO Tel: +441698748832 Dr Duncan Moore Chairman Tel; +447785971715
20th Dec 2012
Alba Bioscience streamlines and improves their compliance processes with Gael
Alba Bioscience announcement
20th Dec 2012
Quantics and YHEC team up to offer Indirect and Mixed Treatment Comparisons
YHEC and Quantics
18th Dec 2012
FUNDING FOR COLLABORATIVE R&D – GO FOR IT! Aquapharm’s success in getting funding for collaborat
Aquapharm is a small but innovative Scottish life sciences discovery company pioneering the development of breakthrough products founded on the vast, untapped chemical diversity of marine micro-organisms. The company's goal is to harness this novel resource to rapidly discover and develop novel pharmaceuticals able to target unmet clinical needs in oncology and multi-drug resistant bacterial infections.
30th Nov 2012
Omega Diagnostics Group PLC - Regional Selective Assistance - Grant funding
Omega, the AIM listed medical diagnostics company focussed on allergy, food intolerance and infectious disease, announces that it has been awarded a Regional Selective Assistance ("RSA") grant of up to £150,000 from Scottish Enterprise.
13th Nov 2012
EMD Millipore and Sistemic Collaborate to Identify Control Markers for Stem Cell Production.
EMD Millipore and Sistemic partnership
6th Nov 2012
Ferring’s European Marketing Authorisation Application accepted for review.
Saint Prex, Switzerland - November 5, 2012 – Ferring Pharmaceuticals announced today that it has received confirmation from European health authorities that the Marketing Authorisation Application (MAA) for its controlled release, removable misoprostol vaginal delivery system (MVDS) has been accepted for review under the decentralised procedure. Ferring is seeking approval for the MVDS for induction of labour in women with an unfavourable cervix, from 36 weeks gestation, in whom induction is clinically indicated.
6th Nov 2012
Premier Research International will manage their compliance activities using Gael's quality manageme
Press Release
5th Nov 2012
CYCLACEL RECEIVES $1.9 MILLION BIOMEDICAL CATALYST MEDICINE GRANT
Press release
5th Nov 2012
TPP Global Development Ltd enters into a collaboration agreement with Sprint Biosciences AB
Download Press Release
17th Oct 2012
Charles River Laboratories Enters Strategic Partnership with AstraZeneca
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has been selected by AstraZeneca (NYSE: AZN) as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).
10th Oct 2012
IMSL to Build Production Facility Thanks to Regional Selective Assistance (RSA)
3rd October 2012
10th Oct 2012
Encap Drug Delivery establishes Hot Melt Extrusion (HME) capability
Livingston, United Kingdom, 8th October 2012
9th Oct 2012
UWI Label - Scots Entrepreneur Celebrates New Investments
Scots Entrepreneur Celebrates New Investments
13th Sep 2012
MGB PRESENTED POSTER AT 52nd ICAAC, SAN FRANCISCO, September 11th 2012
"Disposition of MGB-BP-3, a New Class of Antibacterial Agent, After Oral Administration in a Hamster Model of Severe Clostridium difficile Associated Diarrhoea (CDAD)"
12th Sep 2012
SLA welcomes appointment of Chairman of UK Cell Therapy catapult
The Scottish Lifesciences Association (SLA) welcomes today's appointment of its Chairman, Dr John Brown CBE FRSE to the role of Chairman at the UK Cell Therapy Catapult. The appointment has been made by the Technology Strategy Board, which is setting up a series of Catapults across the UK for advanced technology sectors.
4th Sep 2012
Tissue Solutions Moves to the West of Scotland Science Park
Tissue Solutions Ltd has moved to a new suite of offices at the West of Scotland Science Park having outgrown its current premises in Clydebank. Founded in 2007 as a provider of ethically acquired human tissue for preclinical drug research, Tissue Solutions has grown steadily year on year gaining a strong international reputation. The company has a client profile that includes all the major pharmaceutical companies world-wide, and has distributors in Japan and Israel.
23rd Aug 2012
SLA Member Aquapharm stars on BBC
Talking to the BBC this morning, Aquapharm directors outlined the fascinating search for new pharmaceutical products from microorganisms in the sludge of Scotland's seabed. The company, an SLA founder member, operates out of Oban and Edinburgh and has been highly succesful over many years in securing large amounts of funding to support its world class research.
23rd Aug 2012
SLA congratulates Roslin Cells on their recent success with TSB funding
SLA is delighted to see Roslin Cells secure over £125 K in funding from the Biocatalyst Feasibility Competition. Roslin Cells will use this to
9th Aug 2012
Antibacterial Research: Aquapharm announces discovery of novel antibiotic compound
1st Aug 2012
Gael webinar
Just to let you know that SLA member Gael Ltd will be hosting a free webinar on Wed 29th August – ‘Implementing an effective electronic CAPA Management System’.
31st Jul 2012
Encap Announces $2M Capital Expenditure Programme
Livingston, United Kingdom, 3rd July 2012
27th Jul 2012
Gael Ltd announced as exclusive sponsor of Edinburgh BioQuarter’s 2012 Regenerative Medicine Confere
Gael Ltd has been unveiled as exclusive sponsors of the Edinburgh BioQuarter Regenerative Medicine Conference 2012.
11th Jul 2012
Work starts on £12.5m life sciences research hub in Dundee
By PETER RANSCOMBE Published on Wednesday 11 July 2012 00:00
6th Jul 2012
BioCity Scotland appoints new Managing Director
Former Global Services Solutions director with GE Life Sciences, Fraser Black, has been appointed as managing director of BioCity Scotland, the centre for life science businesses. Black takes over from Ian Webster, acting managing director since the organisation’s launch in January. He brings extensive experience in the life sciences sector to his new role; he joined GE Life Sciences UK in 2005 having previously held VP positions with Amersham Bioscience in both bioscience services and sales and marketing. As president of Hoefer Pharmacia Biotech, a wholly-owned subsidiary of Amersham Biosciences, he re-engineered the company to achieve significant growth and profitability. Between 2005 - 2011 Black held positions in the Life Science Services Division as global director of Business Development, general manager Scientific Asset Services and Global Services Solutions director. At BioCity Scotland Black will oversee the population of the 23-acre site with new and fast-growing bioscience and life sciences companies. He will continue the relationship-building with corporate partners and embed further links with the North Lanarkshire community. Dr Louis Nisbet, BioCity Scotland chairman said, “We are delighted that Fraser Black will lead the next stage of development at BioCity Scotland. In Fraser we have a truly committed individual whose enthusiasm for our work is already infectious. He brings business development experience honed in the international life sciences arena, as well as world-class team-building skills so we are in very good hands.”
22nd Jun 2012
Scottish Lifesciences Association welcomes Scottish Government announcement on Innovation in Health
Scottish Lifesciences Association welcomes Scottish Government announcement on Innovation in Health
21st Jun 2012
Launch of Scottish-Californian stem cell research
Scottish and Californian research scientists are to work together on new medical research that could lead to major breakthroughs for people living with life-threatening conditions.
20th Jun 2012
Sistemic Announces Customer Agreement with Cytori Therapeutics
Cytori to Utilize Sistemic’s SistemQC™ to Strengthen Understanding of Mechanisms & Support Design of Next-Generation Cell Therapies Boston, Mass., USA, June 20, 2012 / B3C newswire / – Sistemic Ltd. (“Sistemic”), a leading provider of microRNA-based problem-solving services and kit-based products, has formed a customer relationship with Cytori Therapeutics (“Cytori”). Cytori will utilize Sistemic’s proprietarySistemQC™ technology platform in its U.S. cardiac cell therapy clinical trial to molecularly characterize adipose-derived stem and regenerative cells (ADRCs). “Research has shown that within adipose tissue, as well as other cell sources like bone marrow, there are multiple distinct cell types that can contribute to efficacy,” commented Sistemic chairman and CEO Jim Reid. “Cytori selecting our SistemQC serves as another validation of our technology, particularly its flexibility to characterize a wide variety of cells for identity and potency, on a molecular level. We could not be more pleased to have reached this agreement with Cytori.” The announcement was made at the 2012 Bio International Convention in Boston, where Mr. Reid is moderating a panel on stem cell therapeutics featuring leaders from the industry, on Wednesday, June 20, at the Boston Convention Center. “SistemQC will be incorporated into our clinical development to understand which cell types within our Celution® System’s autologous heterogeneous population of ADRCs are the greatest contributors to efficacy,” said Douglas Arm, Ph.D., Senior Vice President Operations at Cytori. “With Sistemic’s novel technology, we can strengthen the mechanistic understanding of our cell output and at the same time support the design of next-generation cell therapies.”
20th Jun 2012
$15M investment for new Inverness global R&D base
Inverness is to be the new home for all diabetes research and development into blood glucose monitoring carried out worldwide by international company LifeScan.
24th May 2012
Roslin Institute benefits from the £250M BBSRC UK funding package
www.scotsman.com/business/technology/scots-to-benefit-from-life-sciences-250m-funding-1-2313136
16th May 2012
Angel signs new contract with ReNeuron
Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, has signed a new contract with ReNeuron Group plc (AIM:RENE) to perform GMP manufacturing services in support of the final part of the PISCES Phase 1 clinical trial of its ReN001 stem cell therapy for stroke; the value of the contract was not disclosed.
10th May 2012
Angel Biomedical acquires the assets of a biomaterial and collagen manufacturing business
The Scottish Lifesciences Association wecolmes the recent acquistion by Angel Biomedical Ltd of the assets of an established biomaterial and collagen manufacturing business. Press release below:
7th May 2012
Intercell announces EUR 25.0 million financing
Intercell announces EUR 25.0 million financing from BB Biotech and proposed private placement with selected institutional investors
30th Apr 2012
The BioMedical Catalyst – Competition Open
The BioMedical Catalyst – Save the Date: Tuesday 15th May for the Scottish Information Day
26th Apr 2012
ProStrakan’s Sancuso Approved in Europe
ProStrakan’s Sancuso Approved in Europe
17th Apr 2012
Angel Biotechnology Holdings and TransGenRx Inc. sign £800K contract
Angel Biotechnology Holdings and TransGenRx Inc. sign contract for development of a recombinant interferon product.
12th Apr 2012
Life sciences set to cash in on £180m funding boost
For Link to the Scotsman click here
11th Apr 2012
Board changes at Optos
LONDON, UK, 11 April 2012 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, announces that Louisa Burdett will succeed Christine Soden as Chief Financial Officer when she steps down from this role on 31 May 2012.
3rd Apr 2012
Innovation Centres to support business and university collaboration
To download the press release click here.
2nd Apr 2012
MGB BioPharma ECCMID Poster Abstract Presented
Glasgow based MGB Biopharma which is developing a new class of antibiotic called DNA Minor Groove Binders, announced today that it has published the results of activity of its most advanced drug MGB-BP3 against Gram positive bacteria, including MRSA and vancomycin resistant enterococci. The company presented data at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London on April 2nd.
2nd Apr 2012
Eden Scott partners with BioCity Scotland
Leading Scottish recruitment consultancy Eden Scott has signed a corporate partnership agreement with BioCity Scotland, the life sciences cluster in Newhouse, Lanarkshire.
22nd Mar 2012
SLA welcomes the £100m GSK investment in Scotland
More than £100m investment confirmed for GSK manufacturing in Scotland
15th Mar 2012
MGB Biopharma awarded TSB Proof of Concept grant
TECHNOLOGY STRATEGY BOARD GRANT AWARDED FOR PARENTERAL PROJECT
14th Mar 2012
TSB Funding call for Stratified Medicine – Diagnostics for Adverse or Non-Response
The government is inviting UK companies to apply for funding to develop tests that will identify patients at risk of either suffering an adverse response or not responding to specific therapies.
13th Mar 2012
SLA Chairman joins BioCity Nottingham board
Life Sciences Industry Leader, Dr John Brown, Joins BioCity Nottingham Board
12th Mar 2012
SLA welcomes Welsh Assembly largesse
The Scottish Lifesciences Association is pleased to see the Welsh Assembly Government putting more resources into life sciences. Such bold initiatives are to be applauded and the SLA is working ever more closely with the Scottish Government and its agencies to ensure that the level of resources being allocated to life sciences in Scotland continues to increase. In such a globally competitive industry it is important that Scotland continually reviews its offering to ensure we remain an attractive destination for the life sciences sector
12th Mar 2012
Tissue Solutions Achieve Certification to ISO 9001
We are pleased to announce that Tissue Solutions has been awarded ISO 9001:2008 Accreditation. The award was made through BSI Management Systems (BSI), a world leader in assessing business processes against internationally recognised standards. We are delighted to achieve this accreditation as formal recognition for our commitment to quality and continuous improvement. Customer care has always been at the forefront of our business and ISO certification provides our customers with further reassurance that we always provides a quality service.
6th Mar 2012
Alba Bioscience Parent Company, Quotient Biodiagnostics, Raises $11.2 Million of Growth Finance
Quotient Biodiagnostics Raises $11.2 Million of Growth Finance Led by Galen Partners
5th Mar 2012
Angel Biotechnology appoints Dr. Stewart White as Acting CEO
Angel Biotechnology Holdings plc
5th Mar 2012
Roslin Cells To Manufacture iPS Cells For Bipolar Disorder Research
Roslin Cells Ltd, announced today that it will be participating in a consortium to generate human induced pluripotent stem cells (iPS cells) to study bipolar affective disorder. The consortium led by Professor Andrew McIntosh from the University of Edinburgh is the winner of a 2011 CRACK-IT Challenge organised by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs).
29th Feb 2012
Integrated Magnetic Systems Ltd awarded a SMART R&D grant for “Magnetic Antibodies”
Integrated Magnetic Systems Ltd (IMSL), a bio-nanotechnology company based in Dundee Scotland, announces that it has won a Scottish Enterprise SMART:Scotland R&D award to further develop their proprietary magnetic protein technology.
29th Feb 2012
BioCity Scotland joins forces with Harrison Goddard Foote
BioCity Scotland, the newly-opened life sciences cluster in Newhouse, Lanarkshire, has signed a three-year agreement with leading patent attorneys HGF making them the first corporate partner.
26th Feb 2012
Warning Label Wins Backing from US Business High Flier
An ingenious invention that warns when food or other products are about to expire has won backing from an influential figure in the American aviation industry.
22nd Feb 2012
SLA members successful in Medical Research Scotland PhD programme
The SLA is delighted with recent success with the Medical Research Scotland PhD Studentship Programme. For further information please click here
9th Feb 2012
No Expiry Date on Ingenuity As UWI Technology Claims Major Award
An ingenious Scot’s invention that warns when food or other products are about to expire has claimed one of the biggest accolades in the scientific sector.
9th Feb 2012
SLA welcomes the increased investment in life sciences by the Scottish Government
Health Secretary Nicola Sturgeon announces the launch of a £600K Innovation Fund, much wecolmed by the SLA.
8th Feb 2012
Sistemic to work with TiGenix on landmark rheumatoid arthritis cell therapy product
Download Press release here
20th Jan 2012
Roslin Cellab’s Study Determines BioCision’s CoolCell® Technology to be superior
Download release
19th Jan 2012
Alba Bioscience receives FDA license to sell additional products in the USA
Dowload press release
11th Jan 2012
BioCity Scotland Ltd secures former MSD research site
BioCity Scotland Ltd secures former MSD research site
19th Dec 2011
Plant closure led to birth of firm with global ambitions - Gael Limited
Plant closure led to birth of firm with global ambitions
18th Dec 2011
Reid plans expansion at Sistemic
www.scotsman.com/scotland-on-sunday/business/reid_plans_expansion_for_sistemic_1_2014758
1st Dec 2011
Drs Russell Greig and Alex Chanas join BigDNA Advisory Board
Edinburgh based vaccine development company BigDNA has expanded its Advisory Board with the appointments of Dr Russell Greig and Dr Alex Chanas. Both executives each have over 30 years top-level experience in the pharmaceutical industry - Dr Greig having held senior positions at Glaxosmithkline/SR One and Dr Chanas at Pfizer Ltd.
29th Nov 2011
NuCana BioMed Secures $10.4 Million Series A Financing
Download Press Release
3rd Nov 2011
Michael Moore - Secretary of State for Scotland Visits Quintiles in Livingston
Michael Moore visited Quintiles as part of the SLA's engagement week. Issues discussed included how the Scotland Office can help in regulatory issues that apply to SLA member companies.
25th Oct 2011
The SLA welcomes the New NRS Career Researcher Scheme
The Scottish Lifesciences Association has welcomed the Scottish Government's support of the NRS Career Researcher Fellowship to support the next generation of researchers in NHSScotland. Scott Johnstone, CEO of the SLA said: "This investment will enable SLA member companies to engage with the brightest new researchers in NHSScotland and we are committed to working with the R&D Directors to facilitate this"
24th Oct 2011
The University of Edinburgh agrees a collaboration agreement with GSK
Monday 24th October 2011
20th Oct 2011
Ferring Pharmaceuticals Acquires Controlled Therapeutics
Ferring Pharmaceuticals has acquired Controlled Therapeutics in East Kilbide as part of the Group acquisition.
18th Oct 2011
TPP Global Development enters into a collaboration agreement with the University of Dundee
TPP collaboration with the University of Dundee.
11th Oct 2011
Omega Diagnostics in India move
Omega Diagnostics in India move Alva-based medical testing company Omega Diagnostics has set up a subsidiary in India as it looks to tap into the country's major growth potential for allergy products.
9th Sep 2011
Axis-Shield receives FDA clearance for new anti-CCP assay
Dundee, Scotland, 26 August 2011. Axis-Shield plc (LSE: ASD, OSE: ASD) ("Axis-Shield", the "Company" or the "Group"), the international and innovative in vitro diagnostics company, today announces that a new version of the Company's anti-CCP ELISA kit for the diagnosis of rheumatoid arthritis has been cleared for use by the US Food and Drug Administration ("FDA") under the 510(k) procedure. The new kit increases the assay range and contains changed components for reduced manufacturing costs and improved margins.
8th Sep 2011
Cell characterisation experts Sistemic join the Alliance for Regenerative Medicine
NEWS RELEASE
29th Aug 2011
Eden Scott injects fresh expertise into Life Sciences team
Leading Scottish recruitment consultancy Eden Scott has recruited Lynsay Nixon to its fast-growing Life Sciences team. She brings to the firm a wealth of industry experience and expertise gained from working with several innovative and entrepreneurial life sciences businesses, including ImmunoSolv, Quotient Bioresearch and Aptuit.
25th Jul 2011
SLA Scottish Life Sciences Engagement week
The SLA is mounting the first Scottish Life Sciences Engagement Week this autumn, from 19 – 27 October.
14th Jun 2011
Scottish healthcare technology collaboration to support personalised treatment of cancer
13th Jun 2011
Dr John Brown receives CBE and Kevin Moore an OBE in Queen’s Birthday honours
Edinburgh, 13th June 2011. The Scottish Lifesciences Association is delighted to announce that its Chairman, Dr John Brown, has received a CBE. In the same honours list Kevin Moore, SLA’s newest Board member, has received an OBE.
12th Jun 2011
BIOMEDICAL COMPANIES SET FOR CHARITY BOOST IN SCOTLAND
An innovative new funding initiative developed by Scotland’s most comprehensive medical research charity will provide a significant boost for businesses in the key life-sciences sector.
24th May 2011
Medical testing firm Omega Diagnostics signs US deal
Alva-based medical testing company Omega Diagnostics has signed a deal covering the sale and distribution of its Food Detective kit in the US.
20th May 2011
SLA writes to new Ministers
Edinburgh, 20th May 2011. John Brown, as Chairman of the SLA, has written to Nicola Sturgeon congratulating her on her re-appointment as Cabinet Secretary for Health, and highlighting the SLA’s mission to sustain and grow life sciences in Scotland. John has also written in similar terms to John Swinney as Cabinet Secretary for Finance and to the new Enterprise Minister, Fergus Ewing. In these letters, John identified the following priorities for the SLA:-
13th Apr 2011
SLA appoints David Harrison to the Advisory Board
Edinburgh, 13th April 2011. The Scottish Lifesciences Association has recruited a wide cross section of companies from the medical devices, diagnostics, biopharmaceutical and contract research organisations across Scotland. It is continuing to strengthen the board to enhance the Association’s support for the Scottish economy.
6th Apr 2011
Medical Research Scotland announces an innovative change in funding stream
Following a strategic review of Medical Research Scotland's activities, including a detailed consideration of how our funds are best used to support young people in biomedical research in Scotland, the Trustees have decided to introduce an innovative new funding stream which will replace the traditional Project Grants. The very firm intention is to continue to support the careers of such young people, albeit by a different route.
6th Apr 2011
Sistemic's, SistemRNA platform selected by Redx Pharma for drug development screening
Glasgow, Scotland 6th April 2011; Fast growing Sistemic has signed a master service agreement with Redx Pharma, to provide its SistemRNA™ suite of drug development tools, to accelerate Redx Pharma’s preclinical development pipeline, of over 250new drug candidates.This comes on the back of the successful completion of a project which added significant value to one of Redx Pharma’s lead programmes whilst providing a significant cost saving. The news follows Sistemic’s announcement in February of an 82% increase in sales from the same period a year ago.
28th Mar 2011
SLA appoints John A Brown as Director of Policy
Edinburgh, 28th March 2011. The Scottish Lifesciences Association is delighted to announce the appointment of John A Brown as it Director of Policy. The Scottish Lifesciences Association has made a solid start to it operations in Scotland. Following the announcement to set up a Scottish body in November 2010, the Association has successfully recruited a cross section of companies from the medical devices, diagnostics, biopharmaceutical and contract research organisations across Scotland.
17th Mar 2011
Grant Thornton calls upon the Government to protect R&D tax incentive schemes for all businesses
The Government must protect the incentive schemes that encourage investment in research and development “across the board”, says leading business and financial advisers Grant Thornton, and not be tempted by the findings of the Dyson report to restrict tax benefits to a specific sector or type of technology in this month’s Budget. Grant Thornton says that R&D tax credit provides a clear and demonstrable incentive to invest in innovation, which is vital to the UK and Scottish economy. Suggestions that the Government might scale down this benefit by restricting its availability to ‘high-tech’ organisations, as put forward by Sir James Dyson, is causing concern. Neil McInnes for Grant Thornton in Scotland goes on to say that while finance remains one of the biggest challenges for Scottish companies, R&D tax credits enable many SMEs and start-ups to maintain a sustained R&D programme. He says:
15th Mar 2011
AXIS-SHIELD 2010 PRELIMINARY RESULTS
REVENUES EXCEED £100 MILLION & MAIDEN DIVIDEND ANNOUNCED
3rd Feb 2011
Sistemic Sales Gain Pace in 2011
Glasgow, Scotland, February 2, 2011 / b3c newswire / - Sistemic, focussed on providing microRNA-based problem solving services and kit based products to the life sciences research and development markets, is certainly living up to its high growth expectations and award winning tag as Nexxus, Most Promising Company of the Year and has now started 2011 with a bang. This month the company has signed Master Service Agreements with RedX Pharma based in Liverpool, a subsidiary of a large pharmaceutical company in Cambridge, Massachusetts and not forgetting about their home ground, Glasgow University. The gain in the market has been driven by their solid science aligned with their focused commercial strategy which in turn has driven an 82 % increase in sales from the same month a year ago. This places Sistemic on a very firm footing from which it will further expand its efforts globally over the coming year as well as marks a significant milestone in its growth. Sistemic’s Chief Executive, Jim Reid commented that “….It has been a great start to the year and really confirms the strength and broad applicability of our technologies. Sistemic is about giving our clients more instructive information on their system from microRNA profiling, be it in drug discovery or cell QC. The Sistemic approach gives the knowledge to our clients to guide their future development or business decisions and this unique position is resulting in significant commercial interest. 2011 has started well and we expect this to continue with the company continuing to expand its patent protected portfolio of products and services, increasing its Glasgow & Boston facilities as well as expanding internationally to service its increasing global customer base”. Dr. Neil Murray of RedX Pharma commented “We have found the Sistemic approach unique and compelling and we look forward to developing a long and mutually beneficial relationship with them where they will help us with our drug discovery programmes, to bring new treatments faster, cheaper and with more chance of success to the market”. Sistemic’s primary business is focussed on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology markets and the Cell Therapy community. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells, as well as monitoring the QC of production. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™.
27th Jan 2011
SLA Launches
The SLA is now up and running. From the 1st January 2011 the Scottish Lifesciences Industry has a new association. This group has been formed from the BIA (Scotland) but now covers medical devices and diagnostics. This new association has been welcomed by the Scottish government and industry.
